

abbvie

**AbbVie**

**Website:** [www.abbvie.com](http://www.abbvie.com)

**Collaboration opportunities**

Seeking licensing or collaboration opportunities in immunology, oncology, neurology, and hepatology



**Mr. Bin Li**

Director, Search & Evaluation, JAPAC

**Who I would like to meet in the conference?**

Anyone who is interesting in collaboration with or licensing to AbbVie in immunology, oncology, neurology, and hepatology areas.

AMGEN

**Amgen** 安进

**Website:** [www.amgen.com](http://www.amgen.com)



**Mr. Mingqiang Zhang**

Vice President, Asia R&D

**Who I would like to meet in the conference?**

All aspects of Drug Discovery R&D (especially in China) including government relation, outsourcing and collaborations with academia or biotechs.

AstraZeneca 

**AstraZeneca**

**Website:** [www.astrazeneca.com](http://www.astrazeneca.com)



**Mr. Shoubai Chao**

Sr. VP, Technical Operations and Manufacturing at MedImmune & Pre-president of CBA (The Chinese Biopharmaceutical Association-USA)

**Who I would like to meet in the conference?**



**Boehringer Ingelheim Biopharmaceuticals (China) Ltd.**

勃林格殷格翰

Boehringer Ingelheim BioXcellence™ provides the entire production technology chain from DNA to fill and finish at our facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). We have a total commercial capacity of more than 200,000 liters with flexible scales between 400 and 12,000 liters. For products derived from microbial fermentation technology more than 12,000 liters of commercial capacity with flexible scales from 200 liters to 4,500 liters are installed at our site in Vienna, Austria.

With more than 3,000 employees in biopharmaceutical development, quality and manufacturing Boehringer Ingelheim BioXcellence™ is your sustainable, committed contract development and manufacturing partner - producing value for you.

**Website:**

[www.bioxcellence.com](http://www.bioxcellence.com)

**Collaboration Opportunities**

We can provide CDMO service for pharmaceutical/biopharmaceutical companies with or plan to build up biologics in pipeline. We can provide service in China for China, in China for Global, in global for China, in global for global. Our service will producing value for your licensing franchise.



**Ms. Chelsea Mou**

Associate Director, Business Development & Key Account

Management — Boehringer Ingeheim Biopharmaceutical (China) Ltd.



**BMS** 百时美施贵宝

**Website:** [www.bms.com](http://www.bms.com)

**Ms Ling Mo**

Specialty Strategy Director

**Jiangsu Hengrui Medicine Co., Ltd.**

Hengrui Medicine, a China-based specialty pharmaceutical company with annual net sales of over U.S. \$1.6 billion, is committed to the development, manufacturing and commercialization of human therapeutics especially the innovative drugs to address the unmet medical needs in Greater China and Global presence with branches in USA, EU, Japan.

**Website:** <http://www.hrs.com.cn/>

**Collaboration opportunities**

1. Oncology, surgical drugs, contrast media and anti-infectives on the market.
2. Robust pipeline in multiple therapeutic areas including cancer/hematology, endocrine/metabolic, cardiovascular, autoimmune diseases and pain management
3. Novel TKIs and antibodies (immunooncology), precision medicine and cell therapy under development



**Mr. Lianshan Zhang**

President of global R&D



**Livzon Mabpharm**

Located in Zhuhai, Guangdong, China. Focusing on antibody drug development and commercialization.

**Website:**

[www.livzonmabpharm.com](http://www.livzonmabpharm.com)

**Collaboration Opportunities**

We are interested in in-licensing, out-licensing, as well as joint developing antibody drug candidates for unmet cancer treatment demands.



**Mr. Daotian Fu**

General Manager

**Who I would like to meet in the conference?**

Biotechnological and biopharmaceutical companies



INNOVATION

**Johnson & Johnson**

**Website:**

<https://www.jnj.com/>

**Mr. Dong Wu**

Head of AP Innovation Center

**Mr. Mingde Xia**

Senior Director

**Mr. Jimmy Ren**

COO Lung Cancer Center



**Merck Serono 默克雪兰诺**

**Mr. Michael Chen**

Head of External Innovation China 外部创新总监



**Mr. Larry Lin**

Head of Asia Pacific Innovation Hub BD&L

**Ms. Min Wu**

Executive Director



**Novo Nordisk 诺和诺德**

**Mr. Xichen Lin**

Director of External Innovation Sourcing 外部创新总监

**Who I would like to meet in the conference?**

Biotech companies focusing on developing novel therapeutics towards metabolic diseases including diabetes, obesity, diabetic complications, etc.



INC Research is a global, clinical CRO with over 7,000 employees operating across more than 100 countries worldwide. INC work across the full range of clinical development phases and have experience in a wide range on therapeutic areas including CNS, oncology and general medicine. INC's expansion in Asia Pac over the last 5 years has positioned us a key clinical development partner in the region with almost 900 employees across 19 countries including a strong presence in China, Taiwan, Korea and Japan.

**Website:**

[www.incresearch.com](http://www.incresearch.com)



**Mr. Graham Birrell**  
VP Clinical Development, CNS



**Innovent Biologics** 信达生物制药

**Mr. Blake Salisbury**  
VP Business Development

**Mr. Qinwei Zhou** 勤伟 周  
COO



**Sanofi**

**Mr. Jian Li**  
Director for External Science & Partnering (Asia Pacific) Sanofi R&D

**Sanofi-Aventis** 赛诺菲安万拓

**Mr. 斌辉 Ben 倪**  
Head , Partnering and External Innovation,Asia Pacific

**QuintilesIMS** 昆泰

**Website:**

[www.quintiles.com](http://www.quintiles.com)

**Mr. Tong Guo**

VP

**Mr. Sean Su**

Sr. Director

**Kun Tuo (A Quintiles Company)**

**Ms. Veronica Xia** 夏文璐



**Roche**

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics and cancer medicines. The Roche Group, headquartered in Basel, Switzerland is active in over 100 countries and invested CHF 9.9 billion in R&D in 2016.

<http://www.roche.com/>

<http://www.roche.com/partnering.htm>

**Collaboration Opportunities**

At Roche we are looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionise the standard of care.

**Mr. Steven Hu**

Senior Director & Head of CMC, Roche R&D

**Ms. Yingjie Wu**



**Mr. Joe Zheng**

Senior Manager, biologics strategy

**Who I would like to meet in the conference?**

Companies working on breakthrough innovative new drug R&D

Companies with biologics R&D capabilities

Companies working on combination therapy strategies



**Servier**

Servier is a non-listed international pharmaceutical company headquartered in France. With a strong international presence in 148 countries and a turnover of 3.9 billion euros in 2015, Servier employs more than 21,200 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiology, oncology, metabolism, neuropsychiatry and rheumatology. Thanks to its governance placed in a non-profit foundation, the group reinvests 25 percent of Servier products' turnover in research and development and all of its profits in its growth.

**About Servier China**

Servier's presence in China goes back to 1979. The company established the International Center for Therapeutic Research in Beijing in 2001 and the following year saw the opening of a production site in Tianjin. Headquartered in Beijing, Servier Tianjin Pharmaceutical Ltd. is the leading subsidiary of the Servier Research Group, a non-listed French pharmaceutical company. With more than 1,800 employees across the country, Servier China is focused on four areas of excellence: cardiology, metabolism, neuropsychiatry and oncology. Servier China's objective for the future is to reinforce its existing portfolio and develop partnerships in R&D for the benefit of Chinese patients.

**Collaboration Opportunities**

We are looking for potential in-licensing products on late stage of pharmaceutical development (from 3d phase) in the therapeutic areas of potential synergy:

Cardiology

Diabetes

Oncology

We propose strong sales and marketing infrastructure, high proved performance in market access and local manufacturing opportunities.



**Ms. Cynthia Wang**

BD Director

**Who I would like to meet in the conference?**

We are looking for potential in-licensing products on late stage of pharmaceutical development (from 3d phase) in the therapeutic areas of potential synergy:

Cardiology

Diabetes

Oncology

We propose strong sales and marketing infrastructure, high proved performance in market access and local manufacturing opportunities

**Sinopharm Capital** 国药资本

**Mr. Liang Deng**

Deputy General Manager

**Sino-US Biomedical Investment Association-SUBIA** 中美生物医药创业投资促进会

**Mr. Hongsen (John) Niu** 洪森 牛

President 会长

**Shanghai Center of Biomedicine Development** 上海市生物医药科技产业促进中心

**Website:**

[www.biomed.org.cn](http://www.biomed.org.cn)

**Mr. Feng Tian** 丰 田

Minister of Biotechnology



上海复宏汉霖生物技术股份有限公司

**Shanghai Henlius Biotech, Inc.** 上海复宏汉霖生物技术股份有限公司

Shanghai Henlius Biotech, Inc. is a joint venture company formed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Henlius Biopharmaceuticals Co., Ltd. in December 2009. The company focuses on the development, production and commercialization of mAb biosimilar drugs and novel mAbs using cutting-edge technology.



Products currently in development cover a variety of therapeutic areas including oncology and autoimmune diseases. Our R&D management team has extensive experience in the development and commercialization of a range of monoclonal antibody drugs in such leading international pharmaceutical and biotech companies as Genentech, Amgen, BMS and Eli Lilly. The concept of our drug development lies in global integrative innovation, and we have 3 R&D laboratories located in China (Shanghai), the US (California) and Taiwan (Taipei). Henlius is headquartered in the Shanghai Caohejing High-Technology Park. The total area of our Shanghai R&D laboratory is about 4,300m<sup>2</sup>, incorporating established development platforms of monoclonal antibody drugs. The company has completed the construction of a GMP standard facility with a 12,000 liter capacity, which adopted advanced disposable bioreactors based on the existing manufacturing facilities, ensuring the position of Henlius as a leading domestic antibody therapeutic testing and production site based in China.

In the eight years since its foundation, Henlius has been a leader in antibody drug development in China, completing the IND submissions of 8 product candidates with 13 indications. The most advanced product in our pipeline, the 'Recombinant Murine/Human Chimeric Anti-CD20 Monoclonal Antibody Injection' has completed Phase III enrollment and target NDA in China by 4Q2017. The second product HLX02 „Recombinant Humanized Anti-Her2 Monoclonal Antibody Injection“ have both entered the Phase III study.

**Website:**

<http://www.henlius.com/>

**Collaboration Opportunities**

Seeking strategic partnerships to expand product potential of Henlius' proprietary biosimilar and novel antibodies.

**Mr. Scott Liu**

CEO 首席执行官

**Mr. Cheni Kwok**

Head of BD



**Bioclinica**

**Mr. Kimberly Salgueiro**

CONFERENCE AND EVENT LEAD

**Mr. Hidenori Seshimo**

Director, Business Development and Head of Office, Japan

**Ms. Onglee Weng**

Director, Cardiac Safety

**Nanjing Biomedical Research Institute of Nanjing University** 南京大学 - 南京生物医学研究院

**Website:**

www.nbri-nju.com

**Mr. Xiang Gao** 翔 高

**President** 院长



**Hanmi Pharmaceutical** 韩美医药

**Ms. Lauren Lee**

Executive Director, Global Strategy & Business Development

**Ms. Miyoung Cha**

Director, Global Strategy & Business Development

**Ms. Hannah Song**

Assistant Manager, Global Strategy & Business Development

**TaiwanJ Pharmaceuticals** 台湾景凯生技

**Ms. Ying-Chu Shih** 英珠 石

CEO

**Medicilon** 上海美迪西生物医药股份有限公司

**Mr. Chun-Lin Chen** 春麟 陈

CEO



**Medigen Biotechnology Corp.** 基亚生物科技股份有限公司

Medigen Biotechnology Corp (MBC) was established in late 1999. We carry out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering new drug development, innovative drug discovery, molecular diagnostics, vaccine, and generic drugs.

基亚生物科技股份有限公司成立于1999年底，为结合台湾生技医疗研发能量、具国际临床试验经验、并专注开发抗癌与抗肝脏疾病的新药开发公司。透过过去多年的努力耕耘，已逐渐发展成为全方位的生物医药集团，其事业已涵盖了：新药临床开发、创新生物医药研发平台、分子检测、细胞培养疫苗科技、学名药生产营销等多项事业。

**Website:**

<http://www.medigen.com.tw>

**Collaboration Opportunities**

**1. Muparfostat (PI-88) in Phase III**

Muparfostat (PI-88) is in the leading position in the development of adjuvant treatment for HCC after resection.

Muparfostat (PI-88)小分子药物能抑制肿瘤血管新生及肿瘤细胞转移，

可用于肝癌术后预防肿瘤复发之治疗。

**2. MBC-101 (mAb) in Preclinical stage**

MBC-101 is fully native human monoclonal antibody for severe H1N1 influenza therapy.

MBC-101 是针对 H1N1 病毒直接从人血筛选而出的单株抗体，可用于 H1N1 流行性感冒预防及重症治疗。



**Mr. K Conrad Lai**

Vice President

**Who I would like to meet in the conference?**

Potential licensees or business partner



**Ms Lillian Wang**

Director

**Who I would like to meet in the conference?**

Out-licensing for Oncology product

**Ms Kathleen Wu**

Project Manager

**Who I would like to meet in the conference?**

Potential licensees or business partners

**Mycenax Biotech** 永昕生物医药股份有限公司

**Website:**

[www.mycenax.com.tw](http://www.mycenax.com.tw)

**Mr. Raven LIN**

Head of BD

**Ally Bridge LB Healthcare Fund** 汇桥资本 **LB** 医疗基金

**Mr. Bin Li**

Director 总监



**Andros Pharmaceuticals** 竟天生物科技股份有限公司

Andros Pharmaceuticals Co., Ltd. (Andros Pharma) is a Taiwan-based bio-pharmaceutical company engaged in developing novel drug delivery technologies, currently focusing on the development of new dosage form topical drugs and non-viral gene delivery systems.

In current pipeline, we have drug products in various phases from preclinical to clinical to market. We aim to develop unique and competitive new dosage form drug products of significant market potential, with competitive advantages of multidisciplinary team, proprietary drug delivery technologies, and a PIC/s GMP certified manufacturing facility; these advantages enable Andros Pharma to shorten the product development period, maintain solid quality control, and offer full services of drug development from bench to commercialization.

**Technology**

Andros has developed two proprietary and innovative drug delivery platform technologies to support the development of its pipeline. The first technology focuses on lipid-based/polymer-film topical drug delivery system where drug molecules can permeate into skin effectively and efficaciously, and reduce the skin irritation. Utilizing this topical delivery platform, Andros has generated a pipeline of local anesthetics/analgesics, with one of its lead products currently at the end of clinical trial phase 1 in Taiwan. The second technology, liposomal drug delivery enables non-viral siRNA/anti-sense oligonucleotide to be effectively delivered into target cells with greater efficiency and reduced toxicity.

Andros has comprehensive patent portfolio protecting its technologies and products. With Andros platform technologies, in-house development expertise, and manufacturing capabilities (a PICs/GMP certified plant), Andros is in a great position to develop novel drug delivery products that are both unique and of significant market potential.

We welcome discussions on strategic partnerships and collaborations.

**Website:**

<http://www.androspharma.com/index.aspx?lang=en>

## **Collaboration Opportunities**

Partnering objectives

1. Strategic partnership to out-license Phase 2 lead asset of significant market potential.
2. Co-development partnership by using Andros's proprietary drug delivery technologies and GMP facility to expand clinical and commercial relevant products.
3. Partnership in global sales/distribution for Andros's current products LipoT4N5, LALP Cream, and MNS Solution.

**Ms. Ae-June Wang** 王藹君

President 董事長兼總經理

### **Who I would like to meet in the conference?**

Representatives of Pharmaceutical companies for strategic and distribution partnerships

**EpimAb Biotherapeutics** 岸迈生物

**Website:**

[www.epimab.com](http://www.epimab.com)



**Mr. Chenbing Wu**

CEO

**Ascentage Pharma** 亚盛医药

**Mr. Yingjie Huang**

SVP Clinical Development



**Asieris Pharmaceuticals** 亚虹医药科技有限公司

Asieris Pharmaceuticals is privately held Chinese biopharmaceutical company, dedicated to becoming a provider of re-purposed drugs, with extensive historical clinical data, for other disease indications with unmet medical needs. Our initial therapeutic focus is in oncology and multidrug-resistant infections. Privately funded, in

conjunction with a —National 12/13th 5-Year Important Innovations grant, our lead drug candidate (APL-1202) has been shown to be effective and safe in a Phase 2 clinical trial for non-muscle-invasive bladder cancer (NMIBC). APL-1202 will be the first orally delivered drug to treat this form of bladder cancer and is now in a Phase 3 pivotal trial in China.

**Website:**

[www.asieris.cn](http://www.asieris.cn)

### **Collaboration Opportunities**

APL-1301, other formulations and drug candidates, are in development with the intention to begin international clinical development in compliance with USFDA and EMA standards for registration across the global.

Asieris Pharmaceuticals is pursuing academic and corporate collaborations or partnerships to accelerate development of the oncology and infectious disease pipeline.



**Ms. Dandan Xie**

Sr. BD Manager 高级业务拓展经理

**Who I would like to meet in the conference?**

companies in oncology or urology area



**Bayer**

**Ms. Betty Huang**

Head of Business Development and Licensing, China/APAC

**Ms. Cheryl Yang**

Business Development and Licensing China/APAC


**Helios Biotech**

**Mr. Jinquan Sun**

CEO

**Who I would like to meet in the conference?**

Looking for partners for early drug development and business development as well as CRO.



**BELX Bio-Pharma 貝爾克斯生技股份有限公司:**

BELX Bio-Pharmaceutical Co., Ltd. is a Taiwan-based bio-pharmaceutical company engaged in developing botanical new drugs. The core R&D members of BELX Bio-Pharmaceutical were from Industrial Technology and Research Institute (ITRI), with more than 15 years of experience in botanical new drug development. Products currently in development cover variety of therapeutic areas including oncology and aging-related chronic diseases. The lead product-BEL-X has accumulated more than 15 years of R&D efforts, accomplishing key milestones such as pre-clinical pharmacology and toxicology studies, GACP plantation study, GMP manufacturing with stringent quality controls, and etc. The core technology is well protected by more than 30 approved and pending patent applications around the world as well as proprietary technology know-hows. BEL-X has obtained approvals from both US FDA and TFDA to enter a phase I clinical trial in Taiwan. The trial officially started in June, 2017, and is estimated to finish in the fourth quarter of 2019. Upcoming phase II clinical trial will be conducted as a multi-country study, mainly in China.

貝爾克斯生物科技股份有限公司是一家致力於研發植物新藥的生物科技公司。本公司核心研發成員來自工業技術研究院(工研院)生醫與醫材研究所，執行植物新藥開發已有超過 15 年的經驗。目前研發中的產品涵蓋多個治療領域，包括多種癌症及老化相關慢性病等。公司的主力產品- BEL-X 已累積長達 15 年以上的研發，不僅擁有臨床前藥理毒理試驗、藥材 GACP 栽培、植物藥 GMP 製造、藥材基源鑑定、活性鑑定等核心技术，並擁有超過 30 件專利及 know how。本產品已通過美國 FDA 以及台灣衛服部人體一期臨床試驗申請審查，2017 年 6 月開始進行臨床試驗，預計 2019 第四季完成一期臨床試驗。之後展開的人體二期臨床試驗將進行以中國為主的多國家試驗。

**Website:**

[www.belxbiopharma.com](http://www.belxbiopharma.com)

**Collaboration Opportunities**

Partnering objectives

1. Potential collaborators including venture capital and CRO.
2. Strategic partnership to out-license Phase 1/2 lead asset of market potential.
3. Co-development partnership to accelerate development of oncology, aging-related chronic diseases or other diseases pipeline.



**Mr. Ching-Yuan Lee** 李 清 源

Chief Operation Officer 營運長

**Who I would like to meet in the conference?**

Out licensing and/or co-development partners for botanical new drugs in cancer treatment.

Joint venture partners in China.

**Mr. Shau Feng Chang**

CEO

**Who I would like to meet in the conference?**

Looking for collaboration / business codevelopment partners from Pharma, Botanical drug, CRO, VC

**Biosynergics Inc., 南京博斯金生物**

Biosynergics Incorporation (BSI) is a Nanjing-based start-up biotech company focusing on the discovery and development of the innovative biologics for the unmet medical needs. With our proprietary H3 (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, BSI is committed to the development of biological molecules with superior drug properties and/or with novel mechanism of actions to known and novel drug targets.

Founded in March 2013, Biosynergics is operated by a western-trained professional team with the unique combination of business development, technical operations and customer support. To accelerate the speed of China-based innovative drug development, we have established multiple advanced technology platforms to support our —SynNovation 100 program with the goal to develop first-in-class and/or best-in-class antibody drug candidates to 100



highly-selected drug targets covering oncology, autoimmune, inflammatory, and cardiovascular diseases, most of these targets are either novel or newly-validated in recent years and currently in preclinical and clinical studies around the world. During the past three years, Biosynergics has built up an extensive business relationship with numerous China-based pharmaceutical companies and has successfully delivered multiple therapeutic antibody discovery programs to our highly-valued clients.

Based on our cutting-edge technology and proven-track records, together with our clients and partners, we are striving to bring innovative and affordable biologics to patients around the world.

**Website:**

[www.biosynergics.com.cn](http://www.biosynergics.com.cn)

**Collaboration Opportunities**

Innovative antibody drug discovery and early development; Licensing out of lead candidates; Collaboration

**Mr. Mingjiu Chen**

CEO

**Who I would like to meet in the conference?**

Collaboration on innovative antibody drug development; In-licence antibody drug candidates

**BIRD-C GmbH & Co KG**

**Mr. Werner Lubitz**

CEO/CSO

**CAS/SIMM** 上海药物研究所

**Mr. Xiaojie Lu** 晓杰 陆

CRA 研究员

**CASI (Beijing) Pharmaceuticals, Inc** 英创远达（北京）生物医药科技有限公司

CASI Pharmaceuticals, Inc. is a NASDAQ-listed and US-headquartered (with strong presence in China) leading specialty pharmaceutical company (Nasdaq: CASI) dedicated to in-licensing, development, commercialization and sales of innovative therapeutics for oncology, ophthalmology and other unmet medical needs with a focus on China and the U.S. market. Having a world class management and professional team, our global resources, expertise and experience facilitate to bring innovative products to China market. Successful Track Records of International Licensing Deals with in-licensing 3 innovative oncology products for China. Financially we have strong backing from IDG-Accel, KPCB and others as our shareholders. We have always been insisting academic-focused promoting and marketing approach. We are seeking to in-license innovative patented therapeutics for oncology, ophthalmology and other unmet medical needs in China using our unique China/U.S. integrated approach to accelerate drug development.

CASI has unique core competencies to develop clinical-stage or marketed products for China approval and commercialization; including local capabilities of our subsidiary and R&D center in China with world class in-house medical/ clinical/regulatory teams successfully conducted clinical trials (IMCT) for NCEs and NMEs products with efficiency and speed, and a track record of successful CFDA filings and approvals.

**Website:**

[www.casipharma.com.cn](http://www.casipharma.com.cn)

**Collaboration Opportunities**

CASI seeks in-licensing opportunities for China and the U.S. market rights with regard to:

- Targeted oncology therapies
  - Ophthalmology
  - Innovative, patented therapeutics currently in preclinical and clinical stage
  - Marketed therapeutics currently not available or approved in China
- CASI's in-house proprietary NCE oncology product ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor currently in P2 clinical trials in multiple oncology indications. In addition to its internal programs, CASI has in-licensed three oncology products for Greater China market, including ZEVALIN® for ALL, MARQIBO® for NHL and EVOMELA™ for MM. We expect to enrich our oncology product portfolio and strengthen our therapeutic presence in China by in-licensing additional drug candidates for China approval and commercialization.



**Mr Michael Yu**

BD Director

**Who I would like to meet in the conference?**

R&D, Pharm companies with oncology, ophthalmology, hematology assets to license-out or co-development.



**Cell Signaling Technology**

**Website:**

[www.cst-c.com.cn](http://www.cst-c.com.cn)

**Mr. Aaron Liu**

Senior Manager, Strategic Accounts

**Chendu Huasun Group** 成都华神生物技术有限责任公司

**Website:**

[www.huasungrp.com](http://www.huasungrp.com)

**Ms. Yanhua Xu** 燕华 徐  
General Manager 总经理

**Chendu Yingnuo Bio** 成都因诺生物医药科技有限公司

成都因诺生物医药科技有限公司于 2014 年 8 月在天府新区注册创办。以多年研究产生的组织损伤信号传递系统理论为指导，以调动机体内在自主修复能力为目标，由此而产生的一系列激发人体衰竭器官再生和促进功能恢复的临床应用产品。目前主攻项目是一类细胞信号调控治疗缺血性心脑血管疾病新药的开发。随着团队前期研发工作的推进，现已完成多种原料药的合成，制剂工艺的开发，质控标准的建立，以及临床前药效学和药动学等实验。相关专利已撰写完成，正在通过 PCT 途径进入国际审查阶段,同时准备申请 FDA 新药临床研究的相关文件,计划新药的临床实验。企业核心技术是由公司首席科学家主持研发。研发团队运用了他在美国多年的基础研究成果：微量元素在人体组织损伤信号传递系统中的作用机制，通过重新激活组织损伤信号传递系统，调动机体内在的修复能力,从而达到机体对缺血损伤组织自主再生修复的治疗目的，从根本上解决了人体脏器缺血性损伤无法彻底治愈的医学瓶颈。与此同时结合团队自主研发的靶向给药技术，通过时空特异性药物干预,将对慢性缺血损伤组织的有效修复产生一系列突破性的进展。

**Mr. Xiaozhong Chen** 晓忠 陈  
Co-Founder & COO 联合创始人、首席运营官

**Chengdu Huitai Biomedicine Co.,Ltd** 成都惠泰生物医药有限公司

**Website:**

<http://huitaicn.com/>

**Mr. Jian Yu** 健 余

Deputy General Manager 常务副总

**Anhui Anke Biotechnology (Group) Co., Ltd.**安徽安科生物工程（集团）股份有限公司

**Website:**

[www.ankebio.com](http://www.ankebio.com)

**Mr. Siyi Hu** 思怡 胡

Deputy General Manager 副总经理

**KBP Biosciences** 山东亨利医药科技有限责任公司

**Mr. Zhenhua Huang** 振华 黄

President 董事长

**China Capital Management Co., Ltd.** 中信建投资本

**Website:**

[www.ccmc.csc108.com](http://www.ccmc.csc108.com)

**Ms. Zou Xi**

VP

### **Collaboration Opportunities**

- i focus on equity investment in healthcare area, including pharma, device, service, etc. i'm looking to connect with investors / companies to discuss potential collaborations
- i'm actively looking for orthopedics consumable supplies companies (both domestic and overseas), as potential M&A targets

### **Who I would like to meet in the conference?**

Mr. Harvey He 航飞 何 , 复星医药

## **Chubb** 美国丘博保险集团

One of the four largest insurance companies in the United States .

### **Website:**

<http://baoxian.chubb.com.cn/>

### **Collaboration Opportunities**

Expect to discuss with you the opportunity vs. risk of pharmaceutical industry and share with you solution of risk management.

期待与您探讨医药行业发展中机遇与风险的并存，以及分享风险解决的方案。

### **Ms. Cece Liu** 刘静

Underwriting Manager of Custom Industry Solutions, Asia

### **Who I would like to meet in the conference?**

Expect to discuss with you the opportunity vs. risk of pharmaceutical industry and share with you solution of risk management.

期待与您探讨医药行业发展中机遇与风险的并存，以及分享风险解决的方案。

## **CMIC Pharmaceutical Services (Beijing) Co., Ltd (A**

### **Subsidiary of CMIC HOLDINGS Co., Ltd)**

Since its establishment in 1992 in Tokyo, Japan, CMIC has been leading CRO (Contract Research Organization) business in the country and has been expanding its geographical coverage in Asia, such as China, Taiwan, Hong Kong, South Korea, Singapore, Malaysia, Thailand, Philippines and Vietnam, the most rapidly growing market in the world. This makes CMIC able to manage global/Asian clinical trials with hands-on experiences and expertise to provide our clients with the value-added services to support Phase I-IV clinical trials in various therapeutic areas. Not only monitoring DM/STAT and project management, but also strategic and regulatory affairs consultation which requires strong communication and networking skills with regulatory authorities as well as deep knowledge of regulatory affairs, a service listed in our menu of CRO. Our scope of services is not limited to clinical CRO business, but encompasses such business functions as non-clinical CRO, Contract Development and Manufacturing Organization (CDMO) and Contract Sales Organization (CSO).

**Website:**

<http://www.cmic-holdings.co.jp/e/index.shtml>

**Collaboration Opportunities**

Pharmaceutical Outsourcing Services :

1. Contract Research (CRO) - non-clinical and clinical
2. Contract Development and Manufacturing (CDMO)
3. Contract Sales (CSO)
4. Site Management (SMO)
5. Japan Business Solution
6. Orphan Drug Development

Coverage Countries :

USA, Europe, Japan, South Korea, China, Hong Kong, Taiwan, Singapore, Malaysia, Thailand, Philippines, Vietnam and other APAC Countries

Strengths of Clinical Expertise :

Regenerative Medicine, Immuno-Oncology, Immunology, CNS, Rare Disease, and other therapeutic areas

**Ms Jane Chiu**

Director

**Who I would like to meet in the conference?**

Senior management and/or decision-makers from following companies who have R&D budget to conduct clinical trials in/outside China and/or have plans to commercialize products outside China  
Biotech companies

Biopharmaceutical companies

Pharmaceutical companies

**Covington & Burling LLP**

**Website:**

[www.cov.com](http://www.cov.com)

**Ms. Weishi Li 唯实 李**

Partner

Weishi Li's practice covers a wide range of technology-related transactions across multiple sectors, including the life sciences and hi-tech industries. She has particular expertise in the life sciences sector, having assisted many western and Chinese life sciences companies in structuring and negotiating commercial, corporate and partnering transactions in China, including strategic collaborations, joint ventures, licensing, acquisitions, co-promotion and distribution arrangements.

李唯实律师的执业范围涵盖生命科学和高科技行业等多个科技行业的各种相关交易。李律师在中国的生命科学领域造诣尤深，她已协助许多中西方国家生命科学公司在中国交易的架构、谈判协商、商务和公司

以及合伙交易等事宜，包括战略合作、合资企业、许可、收购、共同推广和营销安排等。

**CROWN BIO** 中美冠科

**Website:**

[WWW.CROWNBIO.COM](http://WWW.CROWNBIO.COM)

**Mr. Ligang Zhang** 立刚 张

Business Development Director

**Ms. Yan Long** 燕 龙

Account Manager

**Delos Capital** 康禧全球投资基金

**Website:**

[www.delos.capital/about.html](http://www.delos.capital/about.html)

**Mr. Ting Xiao** 汀 肖

Founder & Partner 基金联合创始人 合伙人

**Frontline BioVentures** 通和资本

**Mr. Lin Ni**

managing director 董事总经理

Beijing Biocytogen Co.,Ltd 北京百奥赛图基因生物技术有限公司

**Website:**

<http://www.bbctg.com.cn>

**Mr. Yuelei Shen** 月雷 沈

President and CEO 董事长、总经理

**BEIJING IDMO Co., Ltd** 北京艾德摩生物技术有限公司

**Ms. Siying Peng** 思颖 彭

CEO

**DOER Biologics** 浙江道尔生物科技有限公司

Zhejiang Doer Biologics Co., Ltd, based in Hangzhou, is an innovative company specializing in the Multi-Domain Protein drug discovery and development. We are currently building up an innovative

technology-xLONGylation® technology. xLONG is a class of hydrophilic, biodegradable protein polymers comprised of

hydrophilic natural amino acids , which is similar to PEG in conformation, with a large hydration radius, low immunogenicity. Therapeutic peptides and proteins fused with xLONG® sequences significantly increase the hydration radius, with improved stability and prolonged half-life in vivo. Furthermore, we also developed MultiBody® and AccuBody® technology derived from xLONG platform. MultiBody® technology is based on the "fit-for-purpose" principle, which integrates multiple domains with different functions to obtain a "best-in-class" protein drugs. AccuBody® technology platform is designed to accumulated and activated anti-tumor drug, such as bsAb, ADCs, therapeutic Abs in tumor tissues, but not in healthy tissue, to minimize toxicity and create safer, more effective cancer therapies. AccuBody® solves this problem by masking anti-tumor bioactivity and enlarging therapeutic drug to nanometer-size by fusing xLONG sequence which integrated with protease cleavage site. AccuBody® based anti -tumor drugs are accumulated in the tumor by enhanced permeability and retention effect (EPR) of tumor and released anti-tumor activity when xLONG sequence removed by tumor specific-protease.

Based on these three core technology platform, DR101 (long-acting growth hormone), DR105 (long- acting arginase mutant), DR106 (long-acting GLP-1/GCG/FGF21 multiple agonists), DR301 (intravitreal administration of ultra-long-acting anti-VEGF/Ang2 antagonists), DR501(accurate-activated anti-CEA/CD3 bsAb) and other innovative biological drugs had been developed by DoerBiologics. Doer's proprietary technology platform and some of preclinical findings will be revealed in this conference first time.

**Website:**

<http://doerbio.com/>

**Collaboration Opportunities**

DoerBiologics is seeking to secure additional partners and resources to co-develop innovative technology platforms and further speed up its products into clinical development.



**Mr. Yanshan Huang** 岩山 黄

General Manager 总经理

**Fangda Partners** 方达律师事务所

**Website:**



[www.fangdalaw.com](http://www.fangdalaw.com)

**Ms. Diana Li**

Partner 合伙人

### **Fenwick & West LLP 泛伟律师事务所**

泛伟律师事务所（Fenwick & West）总部位于美国硅谷，是高科技和生命科学领域律师事务所中的佼佼者。从 70 年代中期代表苹果公司

（Apple）注册，到 2012 年协助 Facebook 在纳斯达克上市，泛伟帮助诸多世界著名公司成为业界的领头羊并保持其领导地位。

泛伟的中国业务部提供公司法、知识产权法、诉讼以及税法方面的专业服务。我们的法律服务包括为中国公司的设立和融资、跨国并购，以及在美国进行投资及开展经营活动提供相关法律服务。

泛伟的律师对高科技及生命科学领域的中美交易所涉及的商业、法律和文化有着深刻的理解，并能使用流利的中文进行交流。我们不仅深刻地理解中国客户的独特需求，更是美国市场、法律和商业规则的专家。泛伟广博的知识，丰富的经验和优异记录，是我们帮助中国客户在美国成功的基石。近年来我们的成功案例包括：担任阿里巴巴（Alibaba）专门的知识产权律师，在其与雅虎的价值 71 亿美元的交易中为其处理复杂的知识产权问题；在思科（Cisco）以 50 亿美元收购 NDS 集团的交易中担任全权法律代表。在展讯通信被紫光集团以 17.8 亿美元收购案中，全权代表展讯通信（纳斯达克代码：SPRD）。

**Website:**

<https://www.fenwick.com/pages/default.aspx>



**Ms. Sophia Chen** 陈云佳博士

Associate, Intellectual Property 律师

**Who I would like to meet in the conference?**

[http://www.fenwick.com/professionals/Pages/sophiachen\\_chineselangu.aspx](http://www.fenwick.com/professionals/Pages/sophiachen_chineselangu.aspx)。我们律所专注为科技和生命科学公司提供全方面的服务，

我们在上海有分所。我希望进一步了解你们的情况，并介绍我们的服务。

陈云佳律师

**Ms. Vanessa Li**  
Counsel



**Ms. 李若木 Ruomu Li**

资深顾问律师 Counsel, Corporate

**Who I would like to meet in the conference?**

李若木(Ruomu Li) 律师的执业重点是兼并和收购、风险投资、私募投资和一般公司事务。

[https://www.fenwick.com/professionals/Pages/ruomuli\\_chineselangu.aspx](https://www.fenwick.com/professionals/Pages/ruomuli_chineselangu.aspx)

**Fountain Medical (TIANJIN) Co., Ltd.**方恩(天津)医药发展有限公司

**Website:**

[www.fountain-med.com](http://www.fountain-med.com)

**Mr. Dan Zhang** 丹 张

Executive Chairman 董事长

**FountainVest** 方源资本

**Website:**

[www.fountainvest.com](http://www.fountainvest.com)

**Ms. Dianna Qian**

Director 总监

**Frees Fund** 峰瑞资本

**Website:**

<https://www.freesvc.com>

**Mr. Feng Li** 丰 李

Founder 创始合伙人

**FunGenome** 泛诺生物科技

**Website:**

[fungenome.bioon.com.cn](http://fungenome.bioon.com.cn)

**Mr. Jian Chen** 坚 陈

CEO

**Genor Biopharma** 沃森-嘉和生物药业有限公司

**Website:**

[www.genorbio.com](http://www.genorbio.com)

**Mr. Rulei Chen** 如雷 陈

VP of BD & Early R&D 副总裁

**Hainan Puli pharmaceutical** 海南普利制药股份有限公司

**Mr. Mao Zhou** 茂 周

VP 副总经理

**Ms. Minhua Fan** 敏华 范

President 董事长

**Hangzhou Tigermed Consulting Co., Ltd** 杭州泰格医药科技

股份有限公司

**Website:**

[www.tigermed.net](http://www.tigermed.net)

**Ms. Shimin Sun**

Senior Medical Director of the Department of Medical Oncology

**Mr. Ray Wang** 锐 王

商务发展与市场总监

**Mr. 东平 张**

市场部经理

**Mr. 舒明 张**

市场部主管

**Shanghai Genechem Co.,Ltd** 上海吉凯基因化学技术有限公司

**Mr. Jijun Yuan** 纪军 袁

Vice President 副总裁

**Hangzhu Generui Biotechnology** 杭州英百睿生物医药技术有  
限公司

**Website:**

[zxhxxc.bioon.com.cn](http://zxhxxc.bioon.com.cn)

**Mr. Zhenwei Miao** 振伟 苗

President&CEO 总裁兼首席执行官

**Hanmi Pharmaceutical**

**Ms. Miyoung Cha**

Director, Global Strategy & Business Development

**Ms. Hannah Song**

Assistant Manager, Global Strategy & Business Development

**Ms. Lauren Lee**

Executive Director, Global Strategy & Business Development

**Headquarters in Princeton, NJ, USA** 上海健信生物医药科技

有限公司

健信生物（[www.lnlbio.com](http://www.lnlbio.com)）在上海和 Princeton, NJ 两地进行研发和

市场工作。致力于肿瘤免疫新靶点单克隆抗体药物前期新产品研发。第

1 个自主研发肿瘤免疫靶点单克隆抗体新药已经进入临床前/临床开发，

后续多个产品在研，转让开发，融资中。

现诚聘研发 VP 或商务总监/VP，联合创始人加盟，共创一份事业。如

有兴趣加盟，请发简历至 [HR@lnlbio.com](mailto:HR@lnlbio.com)。谢谢！

**Website:**

[www.lnlbio.com](http://www.lnlbio.com)

**Collaboration Opportunities**

Looking for VC (pre-A and A round)  
Looking for early projects licensing out  
Looking for candidates to fill in VP positions

**Mr. 佳建 刘**

创始人

**Hinova Pharmaceuticals** 成都海创药业有限公司

**Website:**

[www.hinovapharma.com](http://www.hinovapharma.com)

**Mr. Yuanwei Chen**

CEO 总经理

**HRYZ BIOTECH** 深圳源正细胞医疗技术有限公司

**Website:**

<http://www.biodiscover.com/news/industry/114119.html>

**Mr. Joe Zhou**

CSO 首席科学家

**IDC Industrial design consultancy (Shanghai) Ltd** 产品化机构

**Mr. Yifei Dai**

IDC China Managing Director IDC 中国董事总经理

**ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd**

宜明昂科生物医药技术（上海）有限公司

**Website:**

<http://immuneonco.com/>

**Mr. Wenzhi Tian**

Chairman & CEO 董事长兼首席执行官

**Innagate Pharma** 杭州英创医药科技有限公司

**Mr. 汉承 张**

CEO 总裁

**Just Biotherapeutics** 杭州奕安济世生物药业有限公司

Just Biotherapeutics China is an integrated design company focused on technologies that will accelerate development of biotherapeutics and substantially reduce their manufacturing cost.

With a number of bionovel & biosimilar products, JustBio China is seeking collaboration opportunities for co-development or Joint-Venture.

**Website:**

<http://www.justbiochina.com/>

**Collaboration Opportunities**

Executives of pharma companies, companies to co-develop or in-licensing proprietary products in the field of oncology / hematology.

**Ms. Lizzy Li 琪 李**

Executive Director Strategy & BD 执行总监 战略&业务拓展

**JW Therapeutics (Shanghai) Co., Ltd.**上海药明巨诺生物科技有限公司

**Mr. Wenjun Sun**

VP, Business Development and Government Affairs 副总裁, 商业发展和政府事务

**Kanghong Pharmaceutical** 成都康弘生物科技有限公司

**Website:**

<https://www.cnkh.com/>

**Mr. Ruan Kun 琨 阮**

CRA 生物新药研究员

**Link Health Group** 广州领晟医疗科技有限公司

Link Health /广州领晟医疗科技有限公司

Research based company in China, focusing on first-in-class new drug development. Currently Link Health has a pipeline covering 9 class 1 new drugs including NCE, peptide and protein. 4 have been moved into clinical stage, while others are in preclinical phase.

Link Health has a flexible business model to manage the research and development works, and its projects are from both licensing in and self development. Currently we have already succeed in 4 licensing in cases and importation registration, and 2 global developments.

**Website:**

[www.healthinlink.com](http://www.healthinlink.com)



## Collaboration Opportunities

### 1. Collaboration on development

We have several drug candidates in both clinical and preclinical stages, with first-in-class new target or MOA, to be explored. We look for collaboration on further clinical development. some examples are --- EG5 target. world leading and fastest oral EG5 target for oncology. --- Carti Tide protein based cartilage repair drug candidates, possibly the only DMD (disease modifying drug) in China for OA, ready for IND.

--- New drug with new MOA for Hematology.

### 2. Financing and investment opportunities

### 3. CRO for clinical trials.

**Ms. Yan Song** 燕 宋

创始人兼 CEO

## Who I would like to meet in the conference?

### 1. collaboration on new target and clinical trials

### 2. financing and investment opportunities

### 3 distribution collaboration (for our drugs to be ready for sale in 2019)

### 4. CRO for peptide.



**Lion TCR Pte Ltd** 广州来恩生物制药有限公司

Lion TCR is a clinical-stage T cell immunotherapy company specialized on the development and commercialisation of its proprietary technologic and T cell products against viral-related cancers, the world leader in HBV specific TCR redirected T cell therapy against HCC.

Lion TCR develop the clinical product pipelines based on its strong world leading technologic foundation. Its proprietary technologic platforms and product candidate were global exclusive licensed from and co-developed with the Singapore A\*Star and TUM, Germany for TCR-T cell against viral related cancers (HCC, NPC), chronic HBV/HDV infection, CAR-T cell therapy against HCC and HBV infection and for gene editing ASO technologic.

**Website:**

<http://liontcr.com/>

## Collaboration Opportunities

Venture Capitalists, fund managers and other institutional investors.

**Mr** 世健 林

首席运营官

1

**NDFCClub- New Drug Founders' Club** 新药创始人俱乐部



**Ms. Bo Lu**

Operation Director

**Who I would like to meet in the conference?**

1



**Nucleus Network**

**Collaboration Opportunities**

big pharmas and vc partners

**Mr. Cameron Johnson**

CEO

**Who I would like to meet in the conference?**

Organisations planning Phase I clinical trials



**Oncolys Biopharma Inc.**

The mission of Oncolys Biopharma is to contribute to the advancement of medical science in the world through bringing innovation to the existing treatments for cancer and serious infectious diseases, using our virology-based new drug discovery technologies. In addition, our long term target is to tackle the challenges in the field of orphan drugs and to address unmet medical needs for patients with intractable diseases around the world.

At present Oncolys has two business segments. In Pharmaceutical Business, Telomelysin (OBP-301), an oncolytic adenovirus immunotherapy is in clinical development targeting various types of solid tumors including melanoma and esophageal cancer. Along with Telomelysin, an anti-HIV drug OBP-601 (Censavudine) and a novel HDAC inhibitor OBP-801 are also under development in the United

States. With strong expertise in drug discovery and development, Oncolys is committed to give very careful attention to maintain the highest ethical and scientific standards in clinical trials and drug development. And we believe that the shortest way to bring innovation to medical science, as set out as our mission, is to license-out our drug candidates at early development stage to large pharmaceutical companies which are more advantaged from perspectives of access to resources and wide distribution network. This idea is reflected in the business model of Pharmaceutical Business.

In Diagnostics Business, we have a unique CTC (circulating tumor cell) detection adenovirus TelomeScan under development, for possible application for companion diagnostics and laboratory tests, as a useful tool to determine prognosis after surgery and early detection of cancer. Currently there are a number of research institutions that use TelomeScan for research purposes both domestically and internationally.

**Website:**

<http://www.oncolys.com/en/>

**Collaboration Opportunities**

In Pharmaceutical Business, we have an anti-HIV drug OBP-601 (Censavudine) and a novel HDAC inhibitor OBP-801 which are both under development in the United States. We would like to seek a partner to develop these drugs in China.

In Diagnostics Business, we have a unique CTC (circulating tumor cell) detection adenovirus TelomeScan under development, for possible application for companion diagnostics and laboratory tests, as a useful tool to determine prognosis after surgery and early detection of cancer. We would like to seek a partner to develop this cancer diagnostics technology in China.

**Mr. Shuichi Isoyama**

Senior Director, BD



**Mr. Zhi Li**

Manager , BD



**Patheon**

Patheon, now part of Thermo Fischer Scientific, is the global CDMO leader. Patheon provides comprehensive development and manufacturing service to pharma clients of all different size. Generally, Patheon can provide below services:

Cell Line Development, Process Development, Analytical Development, Non-GMP manufacturing, GMP manufacturing of mAb and recombinant protein. SS and Single-use bioreactor from 250L-2000L (GMP); Fed-batch, Perfusion, XD process.

Formulation development of drug product, 40+ Dosage Forms in OSD, Softgel and Sterile.

Pre-clinical, clinical material manufacturing and commercial supply for both Drug substance and Drug Product, both Small Molecule and Large molecule.

Small molecule API: 5 sites/Large molecule API:4 sites/Pharmaceutical Development Service (DS): 10 sites/ Commercial manufacturing(DS): 11 sites.

Patheon has 27 locations globally, and has been inspected and approved by 47 different Regulatory Authorities, e.g. FDA, EMA, PMDA, CFDA, KFDA, TGA, etc.

Patheon delivers more successful NDAS than any other CDMO.

Patheon support client to obtain 112 US NDAs for past decade while the next player only get 40.

**Website:**

[www.thermofisher.com/patheon](http://www.thermofisher.com/patheon)

### **Collaboration Opportunities**

Development and manufacturing outsourcing for both Drug Substance and Drug Product, both Small Molecule and Large Molecule



**Mr. Zhang Guo**

Business Development Executive Greater China, Singapore, Australia

### **Who I would like to meet in the conference?**

Companies have outsourcing projects in development or manufacturing

**Pegbio** 派格生物医药（苏州）有限公司

**Website:**

[www.pegbio.com](http://www.pegbio.com)

**Mr. 敏 徐**  
CEO

**Shenzhen GTJA Investment Group** 深圳市高特佳投资集团有限公司

**Mr. 宏武 钮**

执行合伙人 Executive Partner

**Who I would like to meet in the conference?**

1

**Shiyu Capital** 拾玉资本//丹青创新医药投资基金

**Website:**

[www.shiyucapital.com](http://www.shiyucapital.com)

**Mr. 坚 曹**

管理合伙人

**SIBS.CAS** 中国科学院上海生命科学研究院

**Website:**

<http://www.sibs.cas.cn/>

**Mr. 笑人 张**

研究员、研究组长

### **SK biopharmaceuticals (Shanghai)**

SK Biopharmaceuticals was spun out of SK holdings as a new legal entity on April 1st, 2011, and consists of two business areas, new drug development and CMO business. SK Biopharmaceuticals is the first Korean company to obtain IND approval from U.S. FDA. We have an excellent discovery competence in CNS area possessing multiple clinical candidates. We decided to expand therapeutic areas to cancer and diabetes recently.

**Website:**

[www.skbp.com](http://www.skbp.com)

#### **Collaboration Opportunities**

licensing in for oncology

Especially interested in

- CDK4/6

- GBM

- cMet

licensing out for CNS pipelines



**General Manager Kwanghyouk Lee**

**Who I would like to meet in the conference?**

Pharmaceutical companies

Biotech companines

**SSCIP** 中新（成都）创新科技园开发有限公司

新川创新科技园是新加坡首个在中国中西部开发的高科技产业园区（新加坡淡马锡控股与成都高投集团各 50% 合资开发），生物医药是园区重点招商产业。我们意欲打造一个国际化的生物医药产业集群，集聚生物信息技术，转化医学，临床前试验，临床试验研究医院几大产业平台，同时搭建 CRO 生态环境，将整合四川与中国的资源与新加坡生物医药产业环境配合发展。园区目前已经聚集了海思科药业，深圳微芯生物，

四川好医生药业集团，四川协力制药，四川镇泰集团等医药企业，签约企业共 20 家，投资总额 180 亿人民币。 国际招商旨在推介成都的产业资源，并与本地企业建立战略合作，实现跨地理的产业互动，带动地区的产业发展，以城市区域的产业来承载长远的可持续产业升级。

**Website:**

<http://www.sscip.com.cn/>

**Collaboration Opportunities**

新川创新科技园希望在我们大会现场就以下项目与您探讨:

1. 介绍新川创新科技园的产业、城镇规划。
2. 了解企业的研发运营现状以及未来发展的规划，中西部及成都战略。
3. 探索未来合作方向：中国中西部合作；中新合作，探索产业板块的合作及企业可能与新加坡的企业及研究院所之间的合作契机等。



**Ms. 懿林 Yilin DU 杜**

生物医药产业招商总监 Director, Biomedical Industry Promotion

**Who I would like to meet in the conference?**

新川创新科技园希望在我们大会现场就以下项目与您探讨:

1. 介绍新川创新科技园的产业、城镇规划。
2. 了解企业的研发运营现状以及未来发展的规划，中西部及成都战略。
3. 探索未来合作方向：中国中西部合作；中新合作，探索产业板块的合作及企业可能与新加坡的企业及研究院所之间的合作契机等。

**Sundia 桑迪亚医药技术有限责任公司**

**Website:**

[www.sundia.com](http://www.sundia.com)

**Mr. Jiangchang Li 建昌 李**

CEO

**SynCore Biotechnology** 杏國新藥股份有限公司

SynCore focuses on creating values of new drug by R&D management and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI) Taiwan. SynCore's pipeline concentrates on oncology, ophthalmology, and dermatology fields and currently looking for partners for future cooperation and co-development.

**Website:**

[http://www.syncorebio.com/?page=default&lang=us\\_en](http://www.syncorebio.com/?page=default&lang=us_en)

**Collaboration Opportunities**

Licensing out

Co-development

**Mr. Muh-Hwan Su**

General Manager

**Who I would like to meet in the conference?**

Pharma and biotech companies in oncology and ophthalmology. We are currently looking for partners for late stage oncology and ophthalmology assests licensing out or co-development.

**Mr. Todd Ban**

Business Development Manager

**Who I would like to meet in the conference?**

Pharma and biotech companies in oncology and ophthalmology. We are currently looking for partners for late stage oncology and ophthalmology assests licensing out or co-development.

**SYNthesis med chem** 苏州翔实医药

SYNthesis (Suzhou) is preclinical small molecule drug discovery chemistry CRO. We focus on providing the world class medicinal chemistry and synthetic chemistry services by our western-trained medicinal chemists and China-based synthetic chemists. We work seamlessly with our client's research team to add capacity and insight to their drug discovery programs. SYNthesis provide cost effective and flexible chemistry service: from single compound custom synthesis, enriched library synthesis for hit-to-lead and lead



optimisation under FTE arrangement; to risk-sharing integrated drug discovery projects.

Custom synthesis: with a very experienced synthetic chemists based in our Suzhou research facility, we have made a wide range of molecules such as classic heterocyclic molecules, nucleotides, chiral molecules including unnatural amino acids, ADC warheads and linkers, reference compounds and biological tools for chemical biology. We are well equipped to make molecule from mg till multi-kg scale.

Medicinal chemistry: we believe that expert chemists provide the best chemistry and that expert biologists provide the best biology. As Chemistry CRO, we do however provide project management coordinating the interaction between the client, SYNthesis and an appropriate biology CRO to deliver an integrated drug discovery solution. The medicinal chemistry projects we have worked on can be first in class, fast follower, or a simple patent exemplification. We have also worked on a variety of biological targets such as Kinases, Epigenetics, GPCR, HCV, and bacteria. SYNthesis focuses on H2L and LO phase of drug discovery. In last 4 years, 5 clinical candidates have been identified from the work we have carried out for our clients. Risk-sharing drug discovery: Through our risk-sharing Platform, SYNthesis Research based in Australia, we have been working with world-class research organisations and pharmaceutical companies on this dual-contribution/dual-reward, shared risk collaborations, taking advantage of the Australian government's unique R&D tax incentive and SYNthesis med chem 's skills & capabilities in drug discovery chemistry.

**Website:**

[www.synmedchem.cn](http://www.synmedchem.cn)

**Collaboration Opportunities**

Investors interested in small molecule drug discovery projects;  
Companies look for investment or M&A of CRO  
buisness; Pharma/Biotech who look for license in of small molecule  
drug discovery projects;

**Dr Xian Bu**

Cofounder and Managing Director

**Who I would like to meet in the conference?**

Investment companies who are interested in small molecule drug  
discovery projects;  
Pharma or Biotech who are look for licensing in of small molecule  
drug discovery projects;  
Companies who are interested in investing or M&A of our CRO  
business

**Taikangzhijia Capital** 泰康之家投资有限公司

**Mr. 峰 安**

医疗发展事业部助理总经理

### **TiPLab IP Strategy & Management Consulting**

TiPLab 是专注于知识产权的战略管理和商业运营的咨询和研究公司。

基于对创新活跃的技术领域，特别是医疗健康、生命科学等前沿技术领

域的深入研究，TiPLab 通过战略性的知识资产管理，借助独特的计算

机辅助系统来帮助技术驱动型企业获得并维持商业上的竞争优势。

生物医药领域核心服务：

- 1) 全球范围内创设高价值的专利资产；
- 2) 技术实施和商业化方面的风险控制（FTO）；
- 3) 商业活动中的知识产权咨询。

**Website:**

[www.tip-lab.com](http://www.tip-lab.com)

#### **Collaboration Opportunities**

- a) patenting & strategic planning
- b) risk control: FTO
- c) IP DD/consulting during M&A/IPO/financing/exchange etc.

**Ms. 夕多 马**

Operation/Marketing

**Who I would like to meet in the conference?**

Bio-pharmaceutical companies or investors that are interested in IP strategy and risk control.

### **Venture Investments of Johnson & Johnson Innovation 强**

生风险投资

**Website:**

[www.jjdevcorp.com](http://www.jjdevcorp.com)

**Mr. 博 刘**

董事 Principal

**Vigintillion Capital** 惟精资本

**Website:**

<http://company.zhaopin.com/CC483381282.htm>

**Mr. Sam Lou**

创始合伙人

**WIV.CAS** 中国科学院武汉病毒研究所

**Website:**

<http://159.226.126.127:8082/web/21866>

**Collaboration Opportunities**

RNA Vaccine

antiviral

**Mr. Bo Zhang**

PI 研究员

**Who I would like to meet in the conference?**

RNA Vaccine Antiviral Arbovirus

**Yabao Pharmaceutical** 新药创始人俱乐部/苏州亚宝药业集团

股份有限公司

**Website:**

[www.yabao.com.cn](http://www.yabao.com.cn)

**Mr. Peng Wang**

会长、亚宝副总裁

**Yihui Capital** 易汇基金

**Mr. 晓 李**

投资总监、执行合伙人

**Mr. 威 王**

副总裁

**Zovabio** 浙江昭华生物医药有限公司

**Mr. 小冬 曹**

CEO

中美瑞康（南通）生物科技有限公司

**Mr. 龙承 李**

董事长兼总经理

**Sino-US Biomedical Investment Association-SUBIA**

中美生物医药创业投资促进会

**Mr. Hongsen(John) Niu 洪森 牛**

President 会长

同写意论坛发起人 科贝源（北京）生物医药科技有限公司

**Mr. 增江 程**

President 董事长

**Harbin Gloria Pharmaceuticals** 哈尔滨誉衡药业有限公司

[www.gloria.cc](http://www.gloria.cc)

**Mr. Guochun Li 国春 李**

Board Manager & VP 董事兼副总经理



**PuraCap Pharmaceutical LLC** 人福普克药业有限公司

普克药业是中国医药国际化龙头企业，人福医药集团控股公司。目前在美国有四家美国 FDA 认证生产厂及包装配送中心。拥有强大自主研发、生产、销售能力，目前有 5 0 0 个品规的处方药及 OTC 药品在美国市

场销售，覆盖所有美国药店、零售店、政府采购等销售渠道。销售数量及金额为中资企业第一名。连续多年被评为—中国医药制剂出口十大名牌企业II等国家级荣誉。

**Website:**

[www.puracap.com](http://www.puracap.com)

**Collaboration Opportunities**

Companies who like to get into US market and companies who needs investment funds.



**Dahai Guo**

Chairman & CEO

**Who I would like to meet in the conference?**

Companies who is interested in getting into US market. Companies who are looking for investment funds.

**Edding pharm 亿腾药业（泰州）有限公司**

**Mr. William Liang 广鹏 梁**

BD&项目管理副总裁

使徒公司 **Apostle Inc**

在加州硅谷 **Apostle 使徒公司**，我们的科学家致力于研发新型诊断技术 **MiniMax、Triton、AID**，以根本性提高液体活检技术用于癌症早期检测的准确性。

**Website:**

<http://apostlebio.com/>

**Mr. David Ge**

CEO 首席执行官

信达生物制药（苏州）有限公司 **Innovent Biologics, Inc.**

**Mr. Blake Salisbury**

Vice President, Business Development

**Mr. Yunfei Zhang**

商务总监, Director, Business Development

**Mr. Jianqi He**

Associate of BD



先声药业 **Sincere Pharmaceutical Group**

Sincere is a leading Chinese pharmaceutical company specialized in developing and manufacturing innovative medicines and branded generics for oncology, neurology, rheumatology and immunology, as well as for infectious, cardiovascular and metabolic diseases.

Sincere employs approximately 4,000 employees in China. The Company also owns an R&D center, two sales and marketing subsidiaries, and four manufacturing facilities.

Sincere sells over 50 products in China market and has had annual topline growth of over 30% in the past three years. Sincere has a strong development team and distribution network, all managed by industry veterans.

**Website:**

<http://www.simcere.com/>

**Collaboration Opportunities**

Sincere actively seeks out partnership opportunities for both R&D projects and launched products in therapeutic areas such as oncology, neurology, rheumatology and immunology, as well as for infectious, cardiovascular and metabolic diseases.

**Ms. 铭曦 李**

董事会秘书

**Xiaonan Yao**

业务发展经理

**Qifeng Sun**

业务发展经理

**Xin Huang**

总监助理

**Xingyuan Gao**

总监

**Yanyan Liang**

总监

**Kevin Wang**

投资经理

免疫功坊股份有限公司 **Immunwork, Inc.**

**Mr. Tse Wen Chang**

董事長，執行長 **President, CEO**

凯杰（苏州）转化医学研究 **QIAGEN (Suzhou) Translational**

### **Medicine**

QIAGEN (Suzhou) Translational Medicine Co., Ltd. is an innovative company that provides complete solutions for precision medicine. With a state-of-the-art facility equipped with the most advanced technologies and platforms as well as committed talents, QIAGEN (Suzhou) offers our partners with fully integrated solutions from biomarker discovery and lab testing development, patient stratification by molecular testing during clinical trials, to companion diagnostics (CDx) kit development and all the way to commercialization. Based on QIAGEN's advanced technology, and through our knowledge and experience in translational medicine, we sincerely hope to work with you to accelerate the clinical development rate of innovative medicine to make personalized healthcare and improvement in life possible.

凯杰（苏州）转化医学研究有限公司是一个为精准医疗提供完整解决方案的创新型公司。凭借 **QIAGEN** 领先的仪器、试剂以及强大的技术团队，凯杰（苏州）能够为我们的合作伙伴提供从生物标志物的发现和检测方法开发、到新药临床试验病人分子检测和入组筛选，以及伴随诊断试剂盒开发和商业化的一站式服务。我们希望与您携手，通过凯杰先进的核酸和蛋白诊断技术，运用我们的转化医学知识和经验，加快新药临床开发的节奏，为中国待解决的医疗需求提供个体化诊疗解决方案。

### **Website:**

[www.transmedchina.com](http://www.transmedchina.com)

### **Collaboration Opportunities**

凯杰（苏州）可以为精准医疗提供生物标志物的开发、分子诊断产品的

研发，以及临床检测服务等一套完整解决方案。

凭借行业领先的分子检测技术和专业的客户服务，可以和临床合作单位共同完成转化医学研究项目，帮助药企伙伴加快药物研发进程和临床试验病人分型入组，并形成伴随诊断试剂盒产品。



**Mr. Nick Zhang**

Board Chairman and CEO 董事长及首席执行官

**Who I would like to meet in the conference?**

Pharma 制药相关企业

凯石资本

**Ms. 津津 朱**

投资经理

凯莱英生命科学技术（天津）有限公司

**Mr 现 张**

总经理

**Mr 洪夏 何**

高级主管

**Share Capital 分享投资**

**Mr. Frank Su**

管理合伙人 Partner

**Beijing Panacea 北京博纳西亚医药科技有限公司**

**Technology Co., Ltd.**



北京博纳西亚医药科技有限公司是一家专业从事医药研发和临床研究的合同研究组织(CRO)，致力于为化学药品、生物制品、提供临床研究与注册申报的整体解决方案。

博纳西亚自 2004 年成立至今，已成功为国内外近百家客户提供专业技术服务，涉及主要的 20 余个治疗领域，并在国内 20 个主要省市设立办事机构。与全国 80% 的临床试验机构建立了密切合作，拥有一支按照国际标准（ICH-GCP）操作的专业团队，具有完整规范详细的标准操作规程（SOP）。

博纳西亚专注于为客户提供高品质、高效率的专业化服务，缩短产品上市周期，推进产品市场化进程。以专业的技术团队和规范的运营团队为核心优势，以专业高效的服务品质、严谨务实的科学态度为客户提供极具个性化的最佳解决方案，精诚合作、诚信经营。

**Website:**

[www.panacro.com](http://www.panacro.com)

**Collaboration Opportunities**

**CRO**



**Ms. Jennifer Li**

Board Secretary/VP, Head of Sales and Marketing

北京圣沃德生物科技有限公司

**Mr. 捷 张**

**CEO**

北京天佑投资有限公司

**Mr. 世恒 周**

副总经理

**Mr. 新乐 牛**

副总经理

北京爱思益普生物科技股份有限公司

ICE Bioscience is a premier safety and R&D service provider expertise in electrophysiology. Founded in 2010, our highly qualified team of scientists delivers preclinical research solutions in the area of protein expression, cell line development and target screening on ion channels, with particular focus on neuron system and cardiovascular system. ICE has developed over seventy in house ion channel cell lines, covering most voltage-gated and ligand-gated ion channels, including Navs, Kvs, Cavs, GABA, TRP and etc. Our primary goal is to establish functionally validated, high quality ion channel cell lines suitable for use in both manual and automated electrophysiology assays for commercial service purpose, and rapidly increase our portfolio of available ion channel library to meet the sponsors' demands through cell lines development.

Services:

1. Ion channel drug discovery services

70+ in house established ion channel cell lines and positive compound validation databases

2. Cardiac safety screen services

(1) Multiple cardiac safety channels: NaV1.5, CaV1.2, hERG, KvLQT, Kir2.1, KV1.5, KATP, HCN etc.

(2) Cardiac safety screen using iPSCs-derived cardiomyocytes

(3) Cardiac pharmacological study using acute isolated cardiomyocytes (from rabbit, Guinea pig or rats)

(4) Langendorff perfusion isolated heart

(5) Cardiac action potential assays of Purkinje fibers and papillary muscle

3. Neuroelectrophysiology services

(1) CNS & PNS ion channel panel: GABA, NaV, CaV, TRP

(2) Slices electrophysiology, including patch clamp recordings and field potential recordings from brain or spinal cord slices

Address: Floor 3, Building4,35Jinghai 3th Road, E-town Beijing, China, 100176

Tel:

(+86)10-67809840

Email: [services@ice-biosci.com](mailto:services@ice-biosci.com)

Website: <http://www.ice-biosci.com/>

**Website:**

[www.ice-biosci.com](http://www.ice-biosci.com)

**Collaboration Opportunities**

CRO, cardiac safety research, ion channel screen services

**Mr. 英骥 李**

总经理

北京罗杰律师事务所 **Lawjay LLP**

Lawjay is a law firm which focuses on IP litigation.

**Website:**

[www.lawjay.com](http://www.lawjay.com)

**Collaboration Opportunities**

IP consulting and litigation



**Mr. 永全 Richard 刘 Liu**

Partner

**Who I would like to meet in the conference?**

IP manager of pharmaceutical companies.

北京诺诚健华医药科技有限公司 **Beijing InnoCare Pharma**

**Tech**

**Website:**

[www.innocarepharma.com](http://www.innocarepharma.com)

**Collaboration Opportunities**

licensing in/out; Financing/Investment/M&A/Collaboration



**Ms. Jasmine Cui**

董事长兼总裁 President & CEO

**Who I would like to meet in the conference?**

Potential collaborators including new drug discovery company and venture capital

北海康成(北京)医药科技有限公司 **CANbridge**

**Ms. Dan Li**

对外协作及项目管理副总监 Head of Alliance and Program

**Management**

南京凯斯艾生物科技有限公司

**Mr. 永杰 庄**

董事长/CEO

南京友杰医药科技有限公司

**Mr. 援赞 叶**

董事长

南京应诺医药科技有限责任公司

**Mr. 维义 郑**

董事长

南京素鑫生物医药有限公司

**Ms. 景红 张**

创始人, 董事长

印度鲁宾公司 **Lupin Pharma**

**Mr. Kenny Jiang**

首席代表兼中国区负责人 Country Head-Greater China; Chief Representative

同写意新药英才俱乐部/国家新药审评委员会

**Mr. 迅 朱**

理事长/专家

启德医药科技（苏州）有限公司

**Mr. 刚 秦**

董事长/总裁

喜康生物 **JHL Biotech**

**Mr. Weidong Cui**

Vice President of Manufacturing and Technology

国药中生

**Mr. 迂北 滕**

投资主任

国药资本管理有限公司

**Mr. 量 邓**

副总经理

基石药业 **CStone Pharmaceuticals**

**Mr. Andy Fu**

商务拓展与战略高级总监 Sr. Director of BD and Strategy

**Who I would like to meet in the conference?**

companies interested in in-licensing anti-gout agents

companies interested in in-licensing rFVIII

companies interested in potential collaborations in Oncology

基石药业 **CStone Pharmaceuticals**

**Mr. Bing Yuan**

高级副总裁，商业拓展 Senior VP, Global Head of Corporate Development

复星医药

上海复星医药（集团）股份有限公司（简称—复星医药II，证券代码 600196）

成立于 1994 年，1998 年 8 月在[上海证券交易所](#)挂牌上市，是在中国医

药行业处于领先地位的 [上市公司](#)。Fosun Pharma is one of Top 10

pharma, a listed public company in China. Fosun Pharma strategically covers the key sectors of the pharmaceutical and healthcare industrial chain including R&D pharmaceutical manufacturing, medical diagnosis and medical devices and pharmaceutical distribution and retailing and medical services, which contributes to human health.

**Website:**

[www.fosunpharma.com](http://www.fosunpharma.com)

**Collaboration Opportunities**

open for discussion.



**Mr. 航飞 Harvey 何 He**

副总 Deputy General Manager

**Who I would like to meet in the conference?**

杨云霞 董事总经理，红杉资本

赵奕宁 投资合伙人，礼来亚洲基金

钮宏武 执行合伙人，深圳市高特佳投资集团有限公司

苏震波 管理合伙人，分享投资

郭大海 董事长，人福普克药业有限公司

Bin Li 总监，汇桥资本 LB 医疗基金

李 丹 高级总监，北海康成(北京)医药科技有限公司

薛琦 主任合伙人， 上海弼兴律师事务所

Ruomu Li Counsel, Fenwick

**Tasly** 天士力研究院

Tasly Academy was founded in 1994, and has many years' experience of R&D in traditional Chinese medicines, chemical medicine, biomedicine, and so on. Its goal is to establish an open large research platform without tedious hierarchy organization.

Nowadays, Tasly is seeking for out-license chance, our pipeline includes Poly ADP-Ribose Polymerase (PARP) inhibitor, SNDRIs for Depression, NCE for anti-platelet aggregation, AMPK agonist for Hyperlipidemia, and Anti HBV drug.

**Website:**

<http://www.tasly.com/>

**Collaboration Opportunities**

out-licensing 4 pre-clinical drugs

**Ms. Dongxiang Li** 东翔 李

BD Director 业务拓展经理

**Who I would like to meet in the conference?**

Out-licensing for 4 pre-clinical drugs

天津合美医药科技有限公司

**Mr. 和胜 张**

董事长 / CEO

天津和睦健民生物科技有限公司

天津和睦健民生物科技有限公司，创始人是南开大学教授，原生物物理

教研室主任（汪和睦教授），1995年退休后至今一直在从事汉逊酵母

重组乙肝疫苗的开发研究，2015年我们研发成功的汉逊酵母重组

HBsAg-adw 原液产率达 300-400 毫克/升发酵液，创突破性世界领先水平

平，为开发剂量高、产量大和免疫原性强汉逊酵母重组乙肝疫苗奠定了

物质基础。①剂量高：来自于国际高级别循证医学证据，高剂量乙肝疫

苗会获得高免疫应答。我们开发的成人剂量为 40μg /针、儿童剂量为

20 $\mu$ g/针。②产量大：以默克的2台800升发酵罐、或葛兰素史可的1台1500升发酵罐计，高剂量汉逊酵母重组HBsAg原液的年产量为19.8公斤；可分装20 $\mu$ g/针和40 $\mu$ g/针各3亿针，年总产量为六亿针。③免疫原性强：汉逊酵母表达HBsAg利用宿主细胞的类脂组装VLP，由约100个HBsAg组成；HBsAg的226个氨基酸含有14个半胱氨酸，在HBsAg分子内和分子间形成二硫键越多、免疫原性越强，临床试验也证明了汉逊酵母重组乙肝疫苗的保护性抗体滴度免疫应答强。

依据基因重组乙肝疫苗三十年来实践认知，以及依据本人对大连汉逊酵母重组乙肝疫苗10 $\mu$ g/针，0、1、6月免疫三针的临床试验结果，对高剂量汉逊酵母重组乙型肝炎疫苗的免疫效果预期为：儿童和成人疫苗的低/无应答率（抗-HBs滴度<100mIU/mL），将由多数现行疫苗的30%降低至5%以下；儿童的高应答率（抗-HBs滴度 $\geq$ 1000mIU/mL）大于80%；45岁以下成人的高应答率大于70%；实现乙肝疫苗的免疫保护高水平的目标。七年生产高剂量汉逊酵母重组乙肝疫苗35亿至42亿针；对我国有感染乙肝风险的10亿人群（6亿乙肝易感免人群，单一抗-HBc和抗-HBs滴度<100mIU/mL各2亿人群），2030年实现乙肝疫苗免疫保护全覆盖目标。高剂量汉逊酵母重组HBsAg原液产率由三十年来数十毫克，提高至数百毫克，解决人们一直渴望解决但始终未能获得成功的难题；突破了普遍接种、特别是成人接种乙肝疫苗剂量低、产量小和免疫原性弱的瓶颈问题；是实现消除病毒性肝炎目标扩大并加快、加强应对的创新亮点。将提供负担得起、产量大和性价比高乙肝疫苗，为中



国人民服务，并造福世界人民。本项目寻求国内外合作伙伴，一起完成产业化项目。

### **Collaboration Opportunities**

Tianjin Jianmin harmony Biotechnology Co. Ltd., is the founder of Nankai University Professor, former director of the Department of Physics (biology professor Wang, retired in 1995 after peace) has been engaged in research and development in Hansenula yeast recombinant hepatitis B vaccine in 2015, we successfully developed the Hansenula yeast recombinant HBsAg-adw solution was 300-400 mg / L of fermentation liquid, a breakthrough the world leading level, for the development of high dose, high yield and immunogenicity of qianghan Johnson yeast recombinant hepatitis B vaccine laid the material foundation. High dose: from the international high level evidence-based medicine evidence, high dose hepatitis B vaccine will get a high immune response. We developed an adult dose of 40 g/ needles and a child dose of 20 g/ needles. The yield in Mo grams of 2 800 liter fermentor, or Shi Ke's 1 Glaxo 1500 liter fermentor, the high dose of recombinant Hansenula polymorpha HBsAg solution with annual output of 19.8 kilograms; can be divided into 20 g/ and 40 g/ needle needle needle 300 million, annual output of six hundred million pin. The high immunogenicity: Hansenula polymorpha using HBsAg host cell lipid VLP assembly, consisting of about 100 HBsAg; 226 amino acids of HBsAg containing 14 cysteines, forming two disulfide bonds, the more the better immunogenicity in HBsAg within and between molecules, and clinical trials have proved protective antibody titer in response to the strong Hansenula yeast recombinant hepatitis B vaccine. On the basis of recombinant hepatitis B vaccine in thirty years of practice and cognition, based on my own in Dalian Hansenula yeast recombinant hepatitis B vaccine 10 g/ needle, clinical test results of 0 and 1 June three, immune needle, immune effect of high dose of Hansenula polymorpha is expected to Recombinant Hepatitis B Vaccine: the vaccine in children and adults with low / non response rate (anti -HBs the titer of <100mIU /mL), will be reduced by a majority of the vaccine 30% to 5%; the children's high response rate (the titer of anti -HBs than 1000mIU /mL) more than 80% adults under the age of 45; the high response rate of more than 70%; the immunization of hepatitis B vaccine protection high level target. Seven years of production of high dose of Hansenula yeast recombinant hepatitis B vaccine 3 billion 500 million to 4 billion 200 million needles; for our country the risk of hepatitis B infection in 1 billion groups (600 million hepatitis B free susceptible population, single anti -HBc and anti -HBs titer of 200 million <100mIU/mL people)

in 2030, the goal of full coverage of hepatitis B vaccine immune protection. High dose of recombinant Hansenula polymorpha HBsAg liquid yield from thirty years up to hundreds of dozens of Mg, Mg, people are eager to solve problem solving but not always succeed; break the general vaccination, especially adult hepatitis B vaccination dose low yield, small and weak immunogenicity of the bottleneck problem is to achieve the elimination of virus hepatitis; target to expand and accelerate and strengthen the innovation highlights. Will provide affordable, large output and cost-effective hepatitis B vaccine for the Chinese people to serve and benefit the people of the world. The project seeks domestic and international partners to complete the industrialization project.

**Mr 建 李**

总经理

深圳明赛瑞霖药业有限公司

江苏明赛瑞霖药业有限公司是深圳市瑞霖医药有限公司与美国明赛制药股份有限公司合资建立的高新研发企业。公司致力于新药研究开发，目前主要项目是治疗糖尿病视网膜病变和其他并发症的 1.1 类新药。该项目是一国际医药巨头公司多年研发的结晶，有潜力为治疗糖尿病性眼病带来突破性的进展，目前项目将进入 GMP 药学和 GLP 毒理学研究。公司拥有眼科领域国际水准的研发队伍，其研发负责人曾为辉瑞全球眼科研究负责人。公司的目标是要保证研发试验能同时满足中国 SFDA 和美国 FDA 报批临床试验许可的标准。

**Mr. Kai Zhang 凯 张**

CEO

**MabPlex International, LTD.** 烟台迈百瑞国际生物医药有限公司

**Mr Yanbing Wang** 延兵 王

BD Director 业务拓展总监

**Global Law Office** 环球律师事务所

**Mr Alan Zhou**

Partner

**Mr Robert Sun**

Partner

理律法律事务所 **Lee and Li, Attorneys-at-Law**

Lee and Li, a Greater-China law firm, is the oldest law firm in Mainland China and Taiwan. We provide the full and cross-broader legal services through our Greater-China platform and our global network.

Especially, we have established and keep training our Biotechnology Team, comprised of attorneys with backgrounds in law, biotechnology, and biotech-related industries, as well as patent professionals adept in biotechnology and familiar with the biotech industry. Our Biotech Team leverages years of experience in domestic and foreign intellectual property issues, investments, mergers and acquisitions (M&A), initial public offerings (IPO), financing, administrative application, and legal compliance. The Biotech Team provides premium customized and integrated services for the biotech industry.

**Website:**

<http://www.leeandli.com.tw/EN/>

**Collaboration Opportunities**

domestic and foreign intellectual property issues, investments, mergers and acquisitions (M&A), initial public offerings (IPO), financing, administrative application, and legal compliance

**Mr 宗原 Tsung-Yuan** 沈 Shen

资深律师 Senior Attorney

**Who I would like to meet in the conference?**

Pharmaceutical companies, Medical device companies, Applied Biotech companies, and Emerging Biotech companies

**Mr 进治 Angela Hsiao**

法务专员



百奥迈科生物技术有限公司 **Biomics Biotech. Co. Ltd.**

1

**Website:**

<http://www.biomics.cn/cn2/indexc.htm>



**Mr. Jinkang Wang**

VP / CSO

盛世泰科生物医药技术（苏州）有限公司

**Mr. 强 余**

CEO

福建海西新药创制有限公司

**Mr. 心汕 康**

CEO

科锐国际

**Ms. 芸 张**

总监

**Ms. 凤凰 谌**

项目经理

**Ms. 雯静 周**

总监

米度（南京）生物技术有限公司 **MITRO Biotec**

**Mr 成龙 颜**

市场销售总监

**Mr 鹏 方**

高级销售经理

**Mr 腾 赵**

销售经理

**Mr Zheng Wang**

科学顾问委员会主席 Chairman, Science Advisory Board

索元生物医药（杭州）有限公司 **Denovo Biopharma**

**Mr. Wen Luo**

董事长兼总经理

红杉资本 **Sequoia Capital**

**Ms. Lynn Yang**

董事总经理 Managing Director

绿叶制药集团/山东国际生物科技园 **Shandong International**

**Biotechnology Park**

**Mr Tony Jiang**

产业园商业经理

**Mr 征 李**

产业园招商部负责人

舒迪安 **SOTIO**

**Mr 勇 张**

首席医学事务官，商务运营总监

**Ms. 茜 葛**

Clinical Associate

**Mr Vladimir Hrusa**

CEO

艾琪康医药科技（上海）有限公司

**Mr. 寿福 卢**

创始人

苏州克睿基因生物科技有限公司

**Mr. 秋实 李**

COO

苏州工业园区元禾原点创业投资管理有限公司

**Mr. 群 赵**

合伙人

苏州康乃德生物医药有限公司 **Suzhou Connect**

### **Biopharmaceuticals**

**Mr. Bill Pan**

总裁 President

苏州康宁杰瑞生物科技有限公司 **Alphamab (Jiangsu)**

### **Biopharmaceuticals Co.,Ltd**

**Mr. Ting Xu**

CEO

苏州开拓药业股份有限公司

苏州开拓药业股份有限公司成立于 2009 年，位于苏州工业园区生物纳米科技园，是一家致力于创新药物研发的高科技创新企业。公司拥有高素质的研发团队和实验平台，可以进行活性分子设计和合成、体外和动物模型药效测试、药代动力学研究、原料药和制剂研究以及药物初步安全评价等诸多新药临床前的研究。

苏州开拓药业的管理和研究团队是由在美国著名高校获得博士学位的专家带领，他们在美国的制药公司有着多年管理、研发和科技服务的经验；知识结构互补、有良好合作记录和充分接受挑战和风险抗压的能力。公司由获得北京大学学士和硕士、康纳尔大学博士学位的童友之博士任总裁，童博士曾在美国爱因斯丹医学院任教，参与创立美国 Angion 药研公司并出任副总裁，具有丰富的生物药理学术背景和创业型新药研发公司的创建、管理和市场经验；公司由毕业于北京大学，获普渡大学博士学位的郭创新博士担任首席科学官，郭博士曾任美国辉瑞（Pfizer）制药医药化学部主管一职，直接参与领导了多项新药开发，具有丰富的药物化学方面的造诣以及跨国药企的项目管理经验。童友之博士和郭创

新博士分别获得了中组部第八批创业型和第九批创新型“千人计划”特聘专家称号。

公司首个自主研发的新型抑制雄激素受体抗癌创新药物普克鲁胺曾获得国家“十二五”重大新药创制Ⅲ的支持，已于 2015 年初获得中国药监局 1.1 类新药 1-3 期临床批件，现正在进行临床一期的试验；普克鲁胺也已于 2015 年 8 月获得美国 FDA 临床试验批准，目前美国的临床一期试验正在进行，实现了中美两国双报双批双试验。同时该创新药物的新适应症--乳腺癌的临床试验申请正在审批中。

公司主要在研的创新药物项目包括：

1. 新一代抑制雄激素受体的临床抗前列腺癌药物(普克鲁胺，正在中国和美国进行新药的临床试验)；
2. 扩展普克鲁胺用于治疗乳腺癌的适应症；
3. 用于治疗乳腺癌、肺癌和肝癌的 PI3K/mTOR 激酶靶向抑制药物。
4. 预防治疗心血管疾病的 CETP 抑制剂，
5. 治疗关节炎的 JAK2 激酶靶向抑制药物
6. 用于治疗肝癌、卵巢癌和肺癌等多种实体瘤的 FGFR/EGFR 双靶向激酶抑制药物。

自从公司成立以来，公司先后获得过国家“十二五”专项—重大新药创制Ⅲ、科技部中小企业创新基金、江苏省科技支撑计划（社会发展）、苏州市科技计划和姑苏创新创业领军人才专项的资助，其中科技部中小企业创新基金、江苏省科技支撑计划（社会发展）和苏州市科技计划均已结题。



苏州开拓药业自成立以来，先后获得苏州元禾控股有限公司、联想之星、元生创投和弘晖资本的投资。

公司在 2016 年 4 月完成股改，正式更名为苏州开拓药业股份有限公司，2016 年 9 月成功登陆新三板，证券简称：开拓药业；证券代码：839419。

**Website:**

<http://www.kintor.com.cn>

**Collaboration Opportunities**

- 1、项目合作的机会 (collaboration, licensing in/out)
- 2、需要抗体药物工艺研发、申报 CRO/CMO 服务 (biologics/antibody CMC, process development)
- 3、招募高层次人才（药理、临床运营和生物药的发现和工艺研发）High end talent recruitment (pharmacology, clinical operation, medical science/monitoring, biologic/antibody discover/cell line development/process development)
- 4、融资需求 (Financing/investment)

**Mr. 友之 童**

总裁

**Who I would like to meet in the conference?**

- 1、项目合作的机会 (collaboration, licensing in/out)
- 2、需要抗体药物工艺研发、申报 CRO/CMO 服务 (biologics/antibody CMC, process development)
- 3、招募高层次人才（药理、临床运营和生物药的发现和工艺研发）High end talent recruitment (pharmacology, clinical operation, medical science/monitoring, biologic/antibody discover/cell line development/process development)
- 4、融资需求 (Financing/investment)

苏州晶云药物科技有限公司

**Mr. 敏华 陈**

## CEO

苏州泽璟生物制药有限公司

苏州泽璟生物制药有限公司（简称泽璟制药）成立于 2009 年 3 月，是一家由中美医药界精英管理和技术团队共同创办的中外合资企业。全资拥有上海泽璟医药技术有限公司和苏州泽璟生物技术有限公司。泽璟制药致力于创新药物的自主研发、生产和销售。公司具有多个不同阶段的临床新药，其中，发展最快的多纳非尼项目处于晚期肝癌等多个不同肿瘤适应症的 3 期临床后期阶段。

**Website:**

[www.zelgen.com](http://www.zelgen.com)

**Collaboration Opportunities**

New drugs licensing in/out;

Seeking Financing.

**Mr. 彬华 吕**

副总裁

苏州金唯智生物科技有限公司

**Mr Ethan Ge**

全球 CIO 中国区域总经理

苏比亚-蓝石资本

**Ms. 何 季**

副总

英派药业

**Mr. 遂雄 蔡**

Senior VP/CTO

荣森（苏州）新药研发有限公司

Yongsun is a company specializing in the research and development of new drugs in the field of diabetes, the company's founder is an outstanding young scholars in the field of diabetes, medical research in the University of Michigan for many years. He is now a Ph. D. supervisor and professor at Zhejiang University. Our academic results are published in the cover paper of Molecular Cell and are now transforming the results.

**Website:**

/

**Collaboration Opportunities**

Financing & Investment

**Mr. 苏旺 马**

COO

**Who I would like to meet in the conference?**

- 1.Multinational pharmaceutical companies
- 2.Venture Capital

..

**Phagelux 菲吉乐科**



**Mr. 兆荣 陈**

Chief Medical Officer



**Zuellig Pharma 裕利医药**

Zuellig Pharma Specialty Solutions Group (SSG) is a regional consulting and bio-logistics service company and a member of the Zuellig Pharma Group. SSG leverages Zuellig Pharma's cutting edge pan Asian distribution infrastructure to provide value added bio-logistics solutions for pharmaceutical and clinical trial companies.

SSG specializes in clinical trial logistics services, offering consultancy, storage and distribution services for IP, Comparators and Ancillaries through its unrivalled and proprietary network of 15 central and local depots.

We garnered experience from over 1,200 Clinical Trials conducted in controlled ambient, cold chain and ultra-low temperature. The hallmark, a wide range of value added services that include exportation-& importation, labeling, returns & destruction and comparator drug sourcing, differentiates us from the ordinary. Our China team is looking forward to meet you during the DIA exhibition and introduce our services.

裕利医药专业解决方案部（裕利 SSG）是有着 90 多年历史的裕利医药集团旗下的生物咨询和临床试验药品物流服务公司，拥有 14 个中央和地区控制的药品仓储物流中心。

裕利 SSG 主要向制药公司和临床实验公司提供临床试验的咨询，药品仓储和物流服务。其服务范围覆盖从制药实验室到临床研究中心的整合型点到点的供应链服务。

截至目前为止，裕利 SSG 参与并服务超过 1200 多个临床 I, II, III 和 IV 期的实验项目，包括冷冻药品物流；温度控制物流；临床药品仓储；以及其他增值服务如对照药品采购；协助办理临床药品进出口；药品二次包装及临床废料药物销毁等。

裕利 SSG 已进驻中国的临床试验物流领域，希望能以我们多年丰富的实践经验为您提供专业的服务。

**Website:**

[www.zuelligpharma.com](http://www.zuelligpharma.com)

**Collaboration Opportunities**

1. Depot service in 13 countries in Asia ( 14 GCP qualified depot)
  - ü Pacific (including China, India, Taiwan, Australia, Korea)
  - ü USA and EU market
  - ü Study drug storage (15/25°C, 2/8°C, - 20 °C; - 70 °C & -196 °C)
  - ü Distribution

- ü Packaging solutions used for domestic shipment

- ü Returns & destruction

## 2. Comparator drug & Ancillaries supplies

- ü Drug & Ancillaries sourcing

- ü Secondary redressing

- ü Storage and distribution

- ü Site equipment provider

### 3. Secondary repackaging

- ü WHO – GMP certified repackaging

- ü Label printing / Box design

### 4. International Transportation

- ü Temperature sensitive material (15/25°C, 2/8°C, including blood sample exportation)

- ü Import / Export services

## 1. 仓储物流服务（13 个国家， 14 个 GCP 仓库）

- ü 试验药物仓储

- ü 试验药物分销：国内和国际

- ü 试验药物国内物流包装解决方案

- ü 回收和销毁服务

## 2. 参比制剂(原研药)供应

- ü 制剂（原研药）供应

- ü 二次包装

- ü 仓储和分销

## 3. 二次包装

- ü WHO-GMP 环境

- ü 标签印刷/包装盒设计

## 4. 国际运输

- ü 温度敏感产品（15/25°C， 2/8°C， 包括血液样品出口）

- ü 进口/出口服务



**Ms. Hanfang Li**

BD Director

**Who I would like to meet in the conference?**

1. Who are looking for the CTM (storage, distribution, return, destruction, relabeling) partner for clinical trial in China and Asia and Pacific countries
2. Who wants to buy comparators for clinical trial.

**China Novartis Institutes for BioMedical Research**

诺华（中国）生物医学研究有限公司

**Mr. Nanding Zhao**

合作创新总监 Head of External Innovation

贝壳社 **BioClub**

**Mr. 学刚 王**

联合创始人

赛诺菲 **Sanofi**

**Mr. Rick Fang**

杰出科学家 Distinguished Scientific Fellow



## Who I would like to meet in the conference?

- 1) 对创新肿瘤免疫治疗研发项目和初创生物制药公司股权投资感兴趣的投资机构;
- 2) 有兴趣和人工智能开发团队合作的企业(1) investors who are interested in First-in-Class immuno-oncology therapy research and development projects and equity investment in biotech startup; 2) representatives from companies that are interested in collaboration with AI/machine learning algorithm development team)

辉凌制药 **Ferring Pharmaceuticals**

## Mr. Donghui QIN

医药创新总监 Director of Innovation, APAC



通力律师事务所



**Mr** 大立 钱

合伙人

**Frontline BioVentures** 通和资本

**Ms.** 琳 倪

董事总经理

重庆博腾制药科技股份有限公司

**Mr.** 爱武 徐

总经理

**King & Wood Mallesons** 金杜律师事务所

Recognised as one of the world's most innovative law firms, King & Wood Mallesons offers a different perspective to commercial thinking and the client experience. With access to a global platform, a team of over 2000 lawyers in 26 locations around the world works with clients to help them understand local challenges, navigate through regional complexity, and to find commercial solutions that deliver a competitive advantage for our clients.

As a leading international law firm headquartered in Asia, we help clients to open doors and unlock opportunities as they look to Asian markets to unleash their full potential. Combining an unrivalled depth of expertise and breadth of relationships in our core markets, we are connecting Asia to the world, and the world to Asia.

We take a partnership approach in working with clients, focusing not just on what they want, but how they want it. Always pushing the boundaries of what can be achieved, we are reshaping the legal market and challenging our clients to think differently about what a law firm can be.

**Website:**

[www.kwm.com](http://www.kwm.com)

### **Collaboration Opportunities**

Providing comprehensive legal services for Biopharm companies such as corporate, investment, IPR and compliance.

**Mr Chen Wenping** 文平 陈

Partner 合伙人

Mr. Chen Wenping specializes in patent protection.

He has patent expertise in areas such as: pharmaceutical chemistry, bio-technology, medical materials and devices, organic chemistry, synthetic and natural pharmaceuticals, antibiotics, biochemistry, microorganisms, enzyme and protein engineering, genetic engineering, fine chemicals, coatings, cosmetics, detergents and agrochemicals, among others.

Mr. Chen provides various patent services, such as patent application/inquiry/search, patent re-examinations and invalidations, patent infringement analyses, patent administrative and legal proceedings, investigation of patent infringement by administrative authorities, licensing and assignment of patent and know-how, and other matters related to patents. He often represents well-known multinational corporations in patent invalidations and requests for cancellation.



Mr. Chen has been ranked as a —Leading Individualll by Chambers Asia Pacific Guide for consecutive years in the area of intellectual property.

Show moreShow less

Work experience

Mr. Chen Wenping joined King & Wood Mallesons in 2001. Prior to this, he was a patent attorney for 8 years at the Patent & Trademark Law Office of the China Council for the Promotion of International Trade.

He received his B.Sc in Biochemistry from Shanghai Medical Science University and his M.Sc in Bio-pharmaceutics from the Peking Union Medical College. Mr. Chen was admitted as a patent attorney in 1996 and as an attorney-at-law in 2000.

He is proficient in Chinese, English, and French.

Location

**Mr Meng Fanhong** 凡宏 孟

Partner 合伙人

Mr. Meng Fanhong specializes in patent protection related to medicinal biotechnology and chemistry.

Mr. Meng's practice covers a range of areas including biochemistry, biotechnology, pharmaceutical chemistry, organic chemistry, medical devices, chemical engineering and materials, such as, genetic engineering, protein engineering, cell engineering, enzyme engineering, fermentation engineering, natural medicines, synthetic pharmaceuticals, pesticide, cosmetics, detergents, food and beverages, chemical engineering and macromolecular materials.

Mr. Meng has regularly acted for multinational companies on patent application and prosecution, patent strategy, patent advisory, patent search, patent reexamination, patent invalidation, patent infringement analysis, patent infringement litigation, patent administrative litigation, patent and technology licensing and transfer, protection of trade secrets and other matters related to patents.

Show moreShow less

Work experience

Mr. Meng Fanhong rejoined King & Wood Mallesons in 2013. Prior to this, he was a senior IP counsel, Asia Pacific Region in the world-renowned beverage company, and a patent attorney in a large scale domestic IP agency.

Mr. Meng received his B.Sc. and M.Sc. from school of life science of Beijing Normal University. He obtained his LL.M. from Renmin law

school. Mr. Meng was admitted to practice in the PRC in 1998 and a patent attorney in 2000, respectively.

Mr. Meng's working languages are Chinese, English and Japanese.

金林（香港）投资有限公司

**Mr Raymond Chang**  
Managing Director

**Advantech Capital** 尚城投资

**Website:**

<http://www.nhfund.com/>

**Ms. 晶 向**

副总裁

**ZaiLab** 再鼎生物

**Mr. Bo Zhang** 博 张

Senior Director 高级总监

**Mr. Johathan Wang** 翀 王

BD Director 商务拓展部主管

**3DBiopharm 思路迪医药科技公司**

**Mr. 兆龙 John 龚 GONG**

*总裁 President*

**3SBio Inc. 三生制药集团**

**Mr. 祯平 Zhenping 朱 ZHU**

*研发总裁兼首席科学官 President of R&D, CSO*

**6 Dimensions Capital 通和毓承**

**Mr. 忠远 John 朱 ZHU**

*合伙人 Partner*

**Abbott China 雅培中国**

**Mr. Gangfeng 钢锋许 XU**

*Divisional Vice President, Licensing and Acquisitions, China*

**Acesys Pharmatech 南京友杰医药科技有限公司**

**Mr. 援赞叶**

*董事长*

**Advantech Capital 尚诚投资**

**Ms. 晶向**

*副总裁*

**Akeso Biopharma Inc. 中山康方生物医药有限公司**

**Ms. 瑜 Michelle 夏 XIA**

*董事长兼 CEO Chairman & CEO*

**Almac Pharmaceutical Services Pte. Ltd.**

**Mr. Poh-Meng Cheah**

*Sr. Director, Business Development & Marketing*

**Mr. Jonathan Calderwood**

*Commercial Development Director*

**Alphamab (Jiangsu) Biopharmaceuticals Co.,Ltd 苏州康宁杰瑞生物科技有限公司**

**Mr. 霆 Ting 徐 XU**

*CEO*

**Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd. / SAPA-China**

**Ms. 斌 Bin 石 SHI**

*安进亚洲研发中心/SAPA 中国执行会长 Head of External R&D and Licensing Amgen*

*Asia R&D Center/Acting President*

**Anjie Law Firm 安杰律师事务所**

**Mr. Jian Yang**

*Unknown*

**Mr 立吴**

*Partner*

**Ms Rui Wang**

**Aqbio Pharma 艾琪康医药科技（上海）有限公司**

**Mr. 寿福卢**

*创始人*

**Asclepiumm Taiwan 艾斯克立必恩(股)公司**

Asclepiumm Taiwan Co., Ltd. is an early stage therapeutics biotech company developing novel peptide and antibody drugs.

We are developing:

- (1) New peptide drug to block proteolytic networks in angiogenesis for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy,
- (2) Novel antibody to target EMT (epithelial-mesenchymal transition) and possibly has a role in immune-oncology,
- (3) An innovative platform called “Antibody Switch-on Cytotoxicity”, ASC platform to develop antibody-peptide fusion protein drugs which could have dual roles to target

extracellular markers and regulate intracellular signalling pathways at the same molecule for various unmet medical needs.

**Website:**

[www.asclepiumm.com](http://www.asclepiumm.com)

### **Collaboration Opportunities**

Animal studies have already demonstrated the efficacy of these developing drugs. Currently, we are at the beginning stage of our fundraising campaign to complete our wet AMD peptide drugs Phase 1/2a trial by 2020, and to continue developing our anti-cancer antibody drugs as well as the platform for different new drugs.



**Dr. Min-Che Chen**

*Managing Director*

**Ask-pharm 江苏奥赛康药业股份有限公司**

**Mr. 荣马**

*项目经理-战略发展部*

**Asymchem Inc 凯莱英生命科学技术（天津）有限公司**

**Mr. 现张**

*总经理*

**Mr. 洪夏何**

*高级销售总监*

**BeiGene., Ltd 百济神州**

**Mr. 恒 Howard 梁 LIANG**

*首席财务官兼首席战略官 CFO and Chief Strategy Officer*

**Beijing Haidian Hospital 北京海淀医院**

**Mr. 建平徐**

*医师*

**Beijing Innocare Pharma Tech Co.,Ltd 北京诺诚健华医药科技有限公司**

**Ms. 霁松 Jasmine 崔 CUI**

*董事长兼总裁 President & CEO*



**Beijing mabworks Biotech Co.Ltd 北京天广实生物技术股份有限公司**

**Mr. 锋 Feng 李 LI**

*CEO*

**Beijing Shenogen Biotech 北京盛诺基医药科技有限公司**

**Mr. 斌 Bin 叶 YE**

*副总裁 Vice President*

**Betta Pharmaceuticals Co, Ltd 贝达药业股份有限公司**

**Mr. 芬来 Fenlai 谭 TAN**

*董事, 资深副总裁兼首席医学官 Board Member, Senior VP & CMO*

**Bio-Thera Solutions, Ltd 百奥泰生物科技(广州)有限公司**

**Mr. 胜峰 Shengfeng 李 LI**

*总经理 General Manager*



## **Biosion, Inc 博奥信生物技术（南京）有限公司**

Biosion is a biotech company focusing on the discovery and preclinical development of innovative biologicals for unmet medical needs. Leveraging its proprietary H<sup>3</sup> (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is committed to develop antibody drug candidates with optimal specificity and mechanistic drug properties.

The discovery and early development of superior lead candidates with desired properties is a crucial step in all antibody drug programs, and as such, it is the cornerstone of successful antibody drug development. To overcome this limiting step in innovative antibody drug discovery, the Biosion team has established multiple advanced technology platforms to support their "SynNovation 100 program". The goal of the SynNovation 100 program is to develop first-in-class or best-in-class antibody drug candidates to 100 critically reviewed drug targets. The SynNovation 100 drug targets include both novel drug targets as well as newly validated ones based on recent preclinical or clinical studies. Biosion's selected disease areas include cancer, immuno-oncology, autoimmune, inflammatory, and cardiovascular diseases.

During the past several years, Biosion team has successfully delivered multiple therapeutic antibody discovery programs to their clients, which has enabled them to expand their business relationships with numerous pharmaceutical companies. Biosion's cutting-edge technology and proven-track record in the discovery of superior antibody drug candidates has been fueled by their corporate mission of "Innovation for Cures". With this mission, the Biosion team is striving to bring innovative and affordable biologics to patients around the world.

博奥信生物技术(南京)有限公司(Biosion, Inc.)是一家致力于创新抗体药物分子发现与早期开发的海归创业公司。凭借其专有 H<sup>3</sup>抗体技术平台(High-through High-content High-Efficiency Antibody Technology Platform) 和协同抗体技术(SynAb™ Antibody Technology Platform), 博奥信专注开发性能卓越、产品多样、拥有自主知识产权的治疗用抗体药物分子, 为下游合作伙伴提供高性价比药物开发资源, 造福于人类生命健康。

博奥信的“协同创新 100 项目”(SynNovation 100 program) 聚焦 100 个高潜能抗体药物靶点, 系统开展首创(First-in-class)或同类最优(Best-in-class)抗体药物分子的发现与早期开发。其中高潜能药物靶点包括近期发现的新靶点或已进入临床/临床前研究的药物靶点, 适应症涵盖恶性肿瘤、肿瘤免疫、自身免疫性疾病、炎症和心血管疾病等危害人民身体健康的重大疾病。

过去三年, 博奥信团队已成功交付了多个治疗用抗体发现项目, 与业界知名生物制药企业建立了广泛的业务及合作关系。牢记“为患者持续创新(Innovation for cures)”的座右铭, 基于我们国际一流的技术平台、经验丰富的研发团队, 以及高效精准的执行力, 博奥信愿为广大患者开发出“疗效好、用得起”的新一代抗体药物。

### **Website:**

[www.biosion.com](http://www.biosion.com)

### **Collaboration Opportunities**

Biosion is open for strategic alliances with the potential partners, together to achieve greater objectives that are mutually beneficial. Our potential strategic partners include pharmaceutical companies, technology platforms and our downstream partners that can deepen and widen our innovative drug discovery and development pipelines.

1. Anti-Her2 program
2. Multiple programs in I/O, oncology and immunology;
3. Round-B financing investment



**Dr. Mingjiu 明久 Chen 陈**

*总经理*

**Who I would like to meet in the conference?**

Strategic alliance; Co-development; Round-B financing investment

战略合作; 创新抗体药物合作开发; 寻找 B-轮融资机会

**Boehringer Ingelheim 勃林格殷格翰**

**Mr. Henri Doods**

*副总裁, 全球 RBB 部门负责人 VP and Head of Global Research Beyond Borders*

**Bristol-Myers Squibb 百时美施贵宝**

**Ms. Katrin Rupalla**

*副总裁, 开发部负责人 Vice President, Head of Clinical Development, China R&D*

**Ms. Linda Xu**

*Product & Portfolio Strategy Director*

**CanSino Biologics Inc./CBA -The Chinese Biopharmaceutical Association-USA**

康希诺生物股份公司/美国华人生物医药科技协会

**Website:**

[www.cansinotech.com](http://www.cansinotech.com), [www.cba-usa.org](http://www.cba-usa.org)

**Dr. Helen MAO 毛慧华**

*创始人兼高级副总裁 Co-Founder, Senior VP*

**Center Laboratories, Inc. 晟德大藥廠**

Center Laboratories, Inc. (Centerlab), founded in 1957, is currently the largest oral solution pharmaceutical company in Taiwan with more than 70% market share.

Centerlab is also a listed company in Taiwan Stock Exchange Market.

Centerlab is not only known for providing oral solutions to specific medication needs for children, elderly and dysphagia patients. As a versatile company, we are also dedicated to the development of 505(b)(2) and specialty drugs for unmet medical needs.

晟德大藥廠股份有限公司(Center Laboratories, INC.)创立于 1957 年, 目前为台湾最大的内服液剂专业制造药厂, 透过专业处方研究、设计、分析等能力, 提供广大孩童、老人、吞咽困难及特殊病患用药需求之解决方案。除发展多元化新型液体剂型药品, 晟德也致力 505(b)(2)特殊药物开发, 包括糖尿病, 中樞神經(CNS)及癌症治療之新藥, 进军全球市场。

**Collaboration Opportunities**

CS02: A drug candidate potentially restores the impaired beta-cells and improves diabetes care

- Conducting Phase II trial for Type 2 Diabetes in US and Taiwan (expect to complete in 2019/2020)
- High potential of restoring the impaired beta-cells and stop the diabetic progresses
- High potential to treat and reverse both Type 1 and Type 2 Diabetes
- Well established Tox/Pharma data to reduce the cost and risk in development

Co-operation opportunities:

Searching for partnership for further development and commercialization for China and global market

CS01: An oral formulation comprising immediate-release and sustained-release of 2

frequently used drugs for Alzheimer's Disease treatment

- Pilot PK/BE study Completed
- Improvement of convenience and compliance
- Safety of both 2 drugs is already well proofed on market
- Well established clinical data to simplify further clinical study and reduce the cost and risk in development comparing to other CNS drug candidates

Co-operation opportunities:

Searching for partnership for further development and commercialization for China, Asia and global market

**Mr. Eric Shane**

*Chief Development Officer, Specialty Pharma*

**Mr. Luc Tsao**

*Head of BD Division*

**China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR) 诺华(中国)**

生物医学研究有限公司

**Mr. 南丁 Nanding 赵 ZHAO**

*合作创新总监 Head of External Innovation*

**CL Investment Group 乐土投资集团**

**Mr. 志民 Jimmy 张 ZHANG**

*跨境投资董事总经理 Managing Director, Cross-border Investment*



COSECCONSULTING

### **CoSec Consulting Pty Ltd**

CoSec provides the corporate structure and compliance services required to run clinical trials in Australia and qualify for Australia's R&D Tax Incentive.

Our integrated compliance, management and advisory services allows you to fulfil all your regulatory and reporting obligations in Australia. We work closely with a network of trusted services providers - including CROs and legal advisors - to ensure that your objectives for clinical trials are met in Australia.

If you are currently conducting or considering conducting clinical trials in Australia, our services enable you to operate with a minimal local overhead while ensuring you meet and maintain all local regulatory requirements. These requirements are also a core component to qualifying for the R&D Tax Incentive.

The R&D Tax Incentive is the largest single program in Australia to help businesses undertaking research and development. Over \$1.8 billion is awarded annually and it is not competitive - that is, if you are eligible then you are entitled to it. Taking advantage of the R&D Tax Incentive will significantly lower the cost of conducting your clinical trials.

**Website:**

[cosec.com.au](http://cosec.com.au)

### **Collaboration Opportunities**

- Australian Company incorporation
- Australian Government registrations (ASIC, ATO)
- Australian Bank account establishment
- Australian Registered Office / Virtual Office address
- Australian Resident Director
- Australian Resident Public Officer
- Accounting and Bookkeeping Services
- Monthly, quarterly and annual tax filings
- R&D Tax Incentive Advisory Services

## Mr. Paul Dixon

Partner

### Who I would like to meet in the conference?

- Companies interested in conducting research and development (clinical and pre-clinical) in Australia.
- Companies interested in setting up sales and distribution offices in Australia
- VC funds looking to set up investment vehicles in Australia

## Covance

### Mr. Jun Li

### Dr. Dong Yang

Product Development Strategist

## CRC Oncology Corp

### Ms. 钦华 Cindy 茹 RU

总经理 Managing Director

**Crystal Pharmatech** 苏州晶云药物科技有限公司

### Ms. 小玲周

商务经理

## Delos Capital 康禧全球投资基金

Delos Capital is a life sciences venture capital fund founded in 2014 with an office in Central, Hong Kong. The firm currently manages a fund with \$330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is \$10-20M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm can invest both public and private companies in a broad variety of types and transaction structures including growth capital, buyouts, late-stage developments (with proof of concept), and recapitalizations. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

### Website:

[www.delos.capital](http://www.delos.capital)

## Collaboration Opportunities

Investment, licensing out, M&A and collaborations.

## Mr. Tim Xiao

基金联合创始人、合伙人



## DOER Biologics 浙江道尔生物科技有限公司

Zhejiang Doer Biologics Co., Ltd, based in Hangzhou, is an innovative company specializing in the Multi-Domain Protein drug discovery and development. We are currently building up an innovative technology — xLONGylation® technology. xLONG is a class of hydrophilic, biodegradable protein polymers comprised of hydrophilic natural amino acids, which is similar to PEG in conformation, with a large hydration radius, low immunogenicity. Therapeutic peptides and proteins fused with xLONG® sequences significantly increase the hydration radius, with improved stability and prolonged half-life in vivo. Furthermore, we also developed MultiBody® and AccuBody® technology derived from xLONG platform. MultiBody® technology is based on the "fit-for-purpose" principle, which integrates multiple domains with different functions to obtain a "best-in-class" protein drugs. AccuBody® technology platform is designed to accumulated and activated anti-tumor drug, such as bsAb,



ADCs, therapeutic Abs in tumor tissues, but not in healthy tissue, to minimize toxicity and create safer, more effective cancer therapies. AccuBody® solves this problem by masking anti-tumor bioactivity and enlarging therapeutic drug to nanometer-size by fusing xLONG sequence which integrated with protease cleavage site. AccuBody® based anti-tumor drugs are accumulated in the tumor by enhanced permeability and retention effect (EPR) of tumor and released anti-tumor activity when xLONG sequence removed by tumor specific-protease.

Based on these three core technology platform, DR101 (long-acting growth hormone), DR105 (long-acting arginase mutant), DR106 (long-acting GLP-1/GCG/FGF21 multiple agonists), DR301 (intravitreal administration of ultra-long-acting anti-VEGF/Ang2 antagonists), DR501 (accurate-activated anti-CEA/CD3 bsAb) and other innovative biological drugs had been developed by DoerBiologics. Doer's proprietary technology platform and some of preclinical findings will be revealed in this conference first time.

DoerBiologics is also seeking to secure additional partners and resources to co-develop innovative technology platforms and further speed up its products into clinical development.

**Website:**

<http://doerbio.com/>

**Collaboration Opportunities**

biotherapeutic, NASH, obesity, diabetes, cancer, licensing out;co-develop, Financing/Investment

**Dr. 岩山 黄**

*CEO and Founder*

**Who I would like to meet in the conference?**

Big pharma BD who are looking for liscening-in/co-develop biotherapeutic candidate in CVMD and caner area.

**Eight Roads Ventures 斯道资本**

**Mr. 为民 Will 刘 LIU**

*合伙人 Partner*

**EpimAb Biotherapeutics Inc. 上海岸迈生物科技有限公司**

**Mr. 辰冰 Chengbin 吴 WU**

*创始人兼总裁 Founder & CEO*

**Mr. Stephan Lensky**

*首席运营官/商务官 CBO/COO*

**Fosun Kite Biotechnology Co., Ltd 复星凯特生物科技有限公司**

**Mr. 立群 Richard 王 WANG**

*CEO*

**Genequantum 启德医药科技（苏州）有限公司**

**Mr. 刚 Gang 秦 QIN**

*董事长，总裁 President*

**Genor Biopharma Co. Ltd, Walvax Bio Group 嘉和生物药业有限公司**

**Mr. 新华 Joe 周 ZHOU**

*首席执行官 CEO*

**Guangzhou Yuexiu Financial Holdings 越秀金控**

**Mr. 中伏毛**

*投资经理*

**HaiXi Pharma 福建海西新药创制有限公司**

**Mr. 心汕康**

*CEO*

**HighTide Biopharmaceutical**

HighTide is a globally focused, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for people suffering from

gastrointestinal and metabolic disorders with large, unsatisfied markets

**Website:**

[www.hightidebio.com](http://www.hightidebio.com)

**Collaboration Opportunities**

Licensing in and out

Financing

**Dr. LIPING LIU**

创始人

**Who I would like to meet in the conference?**

Crossover investors; MNCs Business Development Executives

**Director of R&D Meng Yu**

**Hinova Pharmaceuticals Inc. 成都海创药业有限公司**

**Mr. 元伟 Yuanwei 陈 Chen**

创始人/董事长 CEO and Founder

**Hua Medicine (Shanghai) Ltd. 华领医药**

**Mr. 力 Li 陈 CHEN**

总裁, 首席执行官联合创始人 President & CEO

**Hutchison MediPharma Holdings Ltd. 和记黄埔医药(上海)有限公司**

**Mr. 焯 Ye 华 HUA**

资深副总裁, 临床研究及注册事务 SVP, Head of Clinical Development & Regulatory Affairs

**I-Mab Biopharma Co., Ltd 天境生物科技(上海)有限公司**

**Ms. 华琼 Joan 申 SHEN**

研发总负责, 副总裁 Head of R&D, Vice President

**IBM**

**Ms. Ran SHEN**

数字营销代表

**Ms. Jing SUN**

Marketing Manager

**Mr. Wei Sun**

数字营销代表

**Mr. Xia 夏 Li 李**

IBM 大中华区全球企业咨询服务事业部医药行业合伙人 Healthcare & Life Science Cluster Lead

**IDG 资本**

关注医疗健康领域的投资

**Website:**

[www.idgvc.com](http://www.idgvc.com)

**Collaboration Opportunities**

医疗健康领域的投资, 微信, 281585371

**Mr. 玄周**

副总裁

**ImmunoChina Pharmaceuticals Co. Ltd 艺妙神州医疗科技**

**Mr. 霆 Ting 何 HE**

CEO

**IMPACT Therapeutics, Inc. 瑛派药业有限公司**

Funded by venture capital and based in China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and "best-in-class" therapeutics to treat cancer and other life-threatening diseases. Since its inception in 2009, IMPACT has made tremendous progress in several oncology drug discovery projects including PARP inhibitors, Hedgehog pathway inhibitors and

microtubule inhibitors. IMPACT closed Series A financing led by Lilly Asia Ventures, Cenova Capital and Wuxi AppTec Ventures in July 2014, and Series B financing from 4 new investors and Lilly Asia Ventures in December 2015.

IMPACT has a highly experienced management team. Dr. Ye Edward Tian, the CEO and CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow, Dr. Tian played critical roles in several drug discovery projects that have advanced to clinical trials. Prior to that, he was a Senior Scientist at Pfizer in Ann Arbor, MI. Dr. Tian received his PhD in Neuroscience and Pharmacology from Michigan State University. Dr. Sui Xiong Cai, the SVP and CTO, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and Cytovia Inc., Dr. Cai has played critical roles in several anticancer projects that have resulted in two drugs in Phase II clinical trials, and is an inventor of more than 80 US issued patents. He received his PhD in Organic Chemistry from University of Oregon.

Our PARP inhibitor IMP4297 has the potential to be developed as a best-in-class for the treatment of cancers with DNA repair defects, including breast, ovarian and prostate cancers with BRCA mutations. First-in-human phase I study of IMP4297 has been initiated in Australia February 2017. An IND application has been approved by CFDA January 2017 and clinical trial in China initiated August 2017.

**Website:**

<http://www.impacttherapeutics.com/english/index.asp>

**Collaboration Opportunities**

Licensing in and out

Financing

Investment

Collaboration

**Mr. 遂雄 Suixiong 蔡 CAI**

高级副总裁兼首席技术官 SVP & CTO

**Impact Therapeutics** 南京英派药业有限公司

**Mr. 野田**

总经理兼首席科学官

**INC Research**

**Mr. Ali Zhu**

BD Manager

**Mr. Marcin Ernst**

VP

**Inclinica (CRO)**

InClinica is a global, clinical contract research organization (CRO) with experience in multiple disease states, drug targets, and device technologies, conducted across all stages of clinical trials.

InClinica specializes in leading companies through all stages of the clinical trial process. Our experience in drug and device development and access to world-class experts, who are critical to trial design and execution, lead to a better anticipation of common and not-so-common mistakes, oversights and assumptions that can derail a study.

InClinica serves all phases of clinical development, with particular strength assisting small to mid-sized companies who are entering first-in-human and phase 2 studies or who need to generate data related to 510k clearance, a de novo 510k application, or a PMA.

An experienced clinical CRO can be the difference between the success or failure of a clinical trial. Discover how InClinica can help move your molecule or your device successfully toward regulatory approval.

**Website:**

[www.inclinica.com](http://www.inclinica.com)

### **Collaboration Opportunities**

Phase I - IV clinical trials

**Ms. Sulakshana Vijayakumar**

#### **Who I would like to meet in the conference?**

Looking forward to meet pharmaceutical, biotech and device companies, interested in conducting high quality clinical studies in Asia Pacific and rest of the world.



**Mr. Marius Jacobsen**

*Director of Business Development, Asia Pacific*

#### **Who I would like to meet in the conference?**

Interested in meeting pharmaceutical, biotech and device companies, looking to conduct clinical trials in Asia Pacific or other parts of the world.

**Innolife Pharm 成都因诺生物医药科技有限公司**

Innolife is an innovative medicine company founded in August 2014 by Dr. Y. James Kang, who launched the "rejuvenation" therapy based on the theory of "tissue injury signaling system".

Innolife is dedicated to provide innovations and solutions for the regeneration of failure organs by discovering, developing original products to mobilize the human body inherent self-repair capability based on the "tissue injury signaling system" regulation to finally realize the rejuvenation and solve the most challenging medical problems.

Innolife core values are driven by a desire to improve human health oriented the human nature, and is committed to being the fugleman of regenerative medicine.

**Website:**

<http://www.innolife.com.cn/>

**Mr. 晓忠陈**

*联合创始人、首席运营官*

**Integrated Development Associates Co., Ltd**

**Mr. John Winebarger**

*President and CEO*

**Ms. Maria Kenjie C. Gaddi**

*Associate Business Development and Administration*

**Irvine Scientific**

**Mr. 见 Jeff 冯 Feng**

*中国区区域经理*

**Ms. 佳妮 Jiani 韩 Han**

*市场助理*

**Kcibiotech 凯斯艾生物科技（苏州）有限公司**

**Mr. 永杰庄**

*董事长*

**KPCB Capital 凯鹏华盈**

**Mr. 瑞晋黄**

*董事总经理*

**Lilly Asia Fund 礼来亚洲基金**

**Mr. 奕宁 Jonathan 赵 ZHAO**

*投资合伙人 Venture Partner*

**Linear Clinical Research**

Linear is the leader for early phase clinical trial services supporting Chinese companies with FDA and EMA submissions. Based in Western Australia (same timezone as China), Linear can accelerate your clinical developments with trial start-up being less than 6 weeks.

Linear 是早期临床试验服务的领导者,为中国公司在 FDA 和 EMA 提交申请提供支持。位于西澳大利亚的 Linear (和中国处于同一时区),可以协助您在 6 周之内完成临床实验前期的所有准备工作,加速临床开发。

+No IND required in Australia to enter Phase 1 +澳大利亚一期临床试验无需 IND  
+Data fully accepted by FDA and EMA + 试验数据完全被 FDA 和 EMA 接受 +The only site to go digital with eSource data collection - quicker more accurate data, and real-time web access to sponsors anywhere in the world. +唯一使用电子数据收集系统的临床试验中心 - 数据收集更加快速和精确,申办方可在世界任何一个地方实时查看数据 +Leaders in complex trials - adaptive designs, Biological therapies, Phase 1 oncology, Diabetes Glucose Clamps, Post-operative studies +复杂试验的领导者 - 适应性设计, 生物疗法, 1 期肿瘤试验, 糖尿病葡萄糖钳夹, 术后研究 +Dedicated China team with Mandarin capabilities +拥有专职的能讲汉语的中国团队

**Website:**

[www.linear.org.au](http://www.linear.org.au)

### **Collaboration Opportunities**

Supporting Chinese Biotechnology companies with Clinical Trial Services.

Strategy and feasibility for Early Phase Trials

Quotes to support capital raising

Introduction to Key Opinion Leaders



**Mr. Jayden Rogers**

*Global Partnering Lead*

### **Who I would like to meet in the conference?**

Look forward to meeting Biotechnology, Pharmaceutical Companies and hospitals to discuss how we can support quicker, more effective clinical trials for global markets.

**Ms. Weiling Fa**

*China Engagement Specialist*

**Link Health Group** 广州领晟医疗科技有限公司

**Ms. 燕宋**

*创始人兼 CEO*

**Mabspacebio** 迈博斯生物医药有限公司

**Mr. 雪明钱**

*创始人, 董事长兼首席执行官*

**McCull Pharmaceutical** 麦科生物/中美生物医药创业投资促进会 **SUBIA-Sino-US Biomedical Investment Association**

**Mr. 洪森 John 牛 NIU**

*CEO/会长 President*



**Medigen Biotechnology Corp.**基亚生物科技股份有限公司

Medigen is a Taiwan-based regional biotech company aiming at developing novel therapies for cancers and liver diseases, and Muparfostat (PI-88) is the leading project in our anti-liver cancer development pipeline. Medigen has recently

developed a third generation NK cell product of precision medicine. We are looking forward to collaboration opportunities of our pipelines for further clinical development and commercialization in the 8th Asia Pharma R&D Leaders.

基亚是一以台湾为总部，专注于抗癌与抗肝脏疾病研发的区域型生物科技公司，Muparfostat (PI-88) 是其抗肝癌研发管线中的领导项目，我们还开发出符合精准医疗之第三代 NK 细胞产品，即将应用于癌症之临床试验上。参加此次会议目的为寻求合作伙伴，以推动后续临床开发及商品化。

**Website:**

<http://www.medigen.com.tw/en/home/>

**Collaboration Opportunities**

Muparfostat (PI-88)

Medigen has recently completed a regional phase III trial in China, Korea, Taiwan and Hong Kong using Muparfostat as an adjuvant therapy for HCC after curative resection. Our phase III data analyses reveals that although Muparfostat did not reach the DFS primary efficacy end point in the ITT population, a subset of patients with microvascular invasion which comprises up to 41% of the total study population, did demonstrate promising benefits out of this therapy. Our phase III data strongly suggested that aside from the known mode of actions of both anti-angiogenesis and anti-metastasis, Muparfostat has additional tumor microenvironment (TME) modulating effects.

基亚近期完成 Muparfostat 肝癌术后辅助治疗三期临床试验，执行区域包括中国、韩国、台湾、及香港等。结果显示虽然主要疗效指针无疾病存活期 (DFS) 未能达到统计显著，但对肿瘤微小血管侵袭 (Microvascular Invasion) 次群体，占原母群体的 41%，分析中显示 Muparfostat 对于预防肿瘤复发具有优良效果。Muparfostat 除原本已知的抑制肿瘤血管新生及抗肿瘤细胞转移作用机制外，三期结果显示其可能亦具有肿瘤微环境调节作用。

**A third generation NK cell product**

Medigen defines a third generation NK cell product for its high purity (>90%), high lytic activity (>90% specific lysis against K562 at E/T = 1) and low percentage of T cell impurity (<0.1%). This product generated by our new process is suitable for both autologous and allogeneic applications. We also develop in vitro diagnostic kits which will help clinicians decide, for each individual patient, what kind of NK cells to use for the best outcome. In the allogeneic NK cell setting another kit is developed, aiming to select the appropriate NK cell donor to the particular patient for an optimal therapeutic results.

由基亚开发的第三代之 NK 细胞符合下列三个条件：(1)高纯度(>90%)，(2)高毒杀活性(对 K562 细胞在 E/T=1 有超过 90%之专一性毒杀活性)及(3)低含量之 T 细胞(<0.1%) 此 NK 细胞产品同时适用于自体(Autologous)及异体(Allogeneic)NK 细胞之培养和应用另基亚开发中的诊断试剂 IVD Kit (In vitro diagnostic kit)可协助医师判断究竟应该用自体或异体的 NK 细胞来治疗某一位特定的病人。若判断应该使用异体的 NK 细胞来治疗，我们也有特殊的 IVD Kit 来协助选择合适的 NK 细胞捐赠者以期达到最好的治疗效果。



**Mr. 冠郎 Conrad 賴 Lai**

*副總經理 Vice President*

**Who I would like to meet in the conference?**

1. CRO for cell therapy
2. Potential partners who are interested in Muparfostat (PI-88) for HCC.



**Ms. 宥人 Lillian 王 Wang**  
事業開發處處長 *BD Director*

**Who I would like to meet in the conference?**

1. Investors
2. Potential partners who are interested in Medigen's pipeline



**Mr. 順浪 Alarng 張 Chang**  
研發長 *Chief Scientific Officer*

**Who I would like to meet in the conference?**

1. Potential partners who are interested in NK cell products.

**Mefund Capital 募方资本**

**Ms. 颖孙**  
投资总监

**Merck Serono 默克雪兰诺**

**Mr. 悦 Yue 黄 HUANG**

临床药理部负责人 *Head of Early Development China*

**MITRO Biotec 米度（南京）生物技术有限公司**

**Mr. 正 Zheng 王 Wang**

科学顾问委员会主席 *Chairman, Science Advisory Board*

**Mr. 成龙颜**

营销总监

**Mr. 腾赵**

销售经理

**Morningside 晨兴创投**

Morningside Ventures is Morningside Group's venture arm founded by the Chan Family of Hong Kong in 1986, focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc.

Morningside Ventures is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

晨兴创投（Morningside Ventures）隶属于晨兴集团，在全球进行高科技风险投资。自1986年创立以来，晨兴创投致力于帮助处于初创期和成长期的生物技术企业，投资涵盖新药研发、临床诊断、医疗器械、医疗服务及数字健康等诸多领域。晨兴创投拥有一支优秀的投资管理团队，多数成员具备公司运营和创业的经验，对于生命科学的前沿、医疗健康产业及不同区域的创业及投资环境，有着深入的理解。

**Website:**

[www.morningside.com](http://www.morningside.com)

**Ms. 丽丽 Lily 沈 SHEN**

董事总经理 *Managing Director*

**MSD R&D (China) Co.,Ltd 默沙东研发（中国）有限公司**

**Mr. 正卿 Zhengqing 李 LI**

全球副总裁兼总经理 *Global VP and General Manager*

**Nanjing Inno Pharm 南京应诺医药科技有限责任公司**

Mr. 维义郑  
董事长

**Nanjing Legend Biotech** 南京传奇生物科技有限公司

Mr. 晓虎 Frank 范 FAN

首席科学官 Chief Scientific Officer

**Nanox Biotech** 纳诺生物科技有限公司

Our tumor targeted delivery canocapsule system is similar to CytomX Probody platform in the way that it "actively" delivers payload to tumor tissue based on tumor associated protease. Hence, the payload is inactive in blood and normal tissue and only active in tumor tissue. It greatly reduced global toxicity and increase therapeutic index of antibody drugs, such as Immuno-Oncology (IO) antibodies, T-cell engaging bi-specific antibodies, and ADCs. Because our system is nanocapsule, it also has features such as payload protection (payload is encased in nanocapsule in blood and normal tissue) and sustained release (as we can see in our EGFR-mab-Nanox on mouse glioma ex vivo study). Our system is great for product differentiation for IO antibodies, T-cell engaging bi-specific antibodies, and ADCs.

### **Collaboration Opportunities**

licensing in/out; Investment; Collaboration

Mr. 进刘

总裁

**New Drug Founders Club** 新药创始人俱乐部

Ms. 波卢

运营总监

Ms. 克柔郑

运营助理



**Nihon Servier Co., Ltd** 施维雅日本

Who we are

- Servier is an international and independent pharmaceutical group, governed by a non-profit Foundation(Nihon Servier is the Japanese subsidiary of Servier)
- We have considerable expertise in the discovery, development and commercialization of therapeutics for diverse fields of medicine including cardiovascular and metabolic diseases, oncology, CNS and rheumatology.
- Servier has an annual turnover of €4 billion, 25% of which (excluding generics) is invested in R&D.
- We employ over 21000 people and our products are available in 148 countries.

What do we bring to our partners?

- A proven track record in clinical development, including large-scale outcome studies
- A strong network of contacts and an excellent reputation with top experts.
- Considerable R&D capacities, including 2200 exclusively dedicated staff, in France and in 19 International Centers for Therapeutic Research.
- Innovative and flexible partnering deals.
- Partnerships managed by dedicated and trained alliance professionals.
- Own commercial operations in over 90 countries worldwide.

**Website:**

<https://servier.com/en/home/>

**Collaboration Opportunities**

What are we looking for?



- We source opportunities in 5 domains to complement internal research: Cardiovascular Disease, CNS with a focus on Neuro-psychiatric disease, Diabetes, Oncology and Immuno-Inflammatory disease.
- We are interested in all types of innovative/—best-in-class” products from target to late clinical phases, provided they bring true therapeutic innovation to areas of unmet medical needs.
- We are also interested in licensing marketed, or near-market products.

Deal types?

- Worldwide rights
- Local & Regional deals.
- R&D collaboration to start either directly, or after option exercise.

**Mr. Eric DELARGE**

*General Manager*

**Novartis** 美国诺华制药公司

**Mr. 彬 Bin 彭 PENG**

*全球肿瘤转化医学上海中心执行总监 Global Head of TCO Shanghai*

**Novo Nordisk** 诺和诺德制药有限公司

**Mr. 保平 Baoping 王 WANG**

*中国研发中心总裁 President*

**Novotech**

**Mr. Edmond Liang**

*Associate Director, Client Operations*

**Oncolys Biopharma Inc.**

The mission of Oncolys Biopharma is to contribute to the advancement of medical science in the world through bringing innovation to the existing treatments for cancer and serious infectious diseases, using our virology-based new drug discovery technologies.

**Website:**

<http://www.oncolys.com/en/>

**Collaboration Opportunities**

We are seeking out-license collaboration opportunities for the products as bellow.

1) OBP-401 (TelomeScan) is a genetically engineered adenovirus type 5 to detect tumor cells. It has a human hTERT gene promoter sequence in the upstream region of virus E1 gene which is responsible for replication of adenovirus, and a GFP gene in E3 region under the control by cytomegalovirus promoter.

2) OBP-801 is a histone deacetylase (HDAC) inhibitor, having specific and strong activity on HDAC, which is expected to show anticancer effect by promoting an expression of tumor suppressor genes in cancer cell and inducing apoptotic and autophagic cell death.

3) OBP-601 (Censavudine) is a novel small molecule nucleotide reverse transcriptase inhibitor (NRTI) for HIV infection and is effective on a wide range of resistant virus strains.



**Mr. Zhi Li**

*BD Manager*

**Who I would like to meet in the conference?**

We are seeking out-license collaboration opportunities for the products as bellow.

1) OBP-401 (TelomeScan) is a genetically engineered adenovirus type 5 to detect tumor cells. It has a human hTERT gene promoter sequence in the upstream region

of virus E1 gene which is responsible for replication of adenovirus, and a GFP gene in E3 region under the control by cytomegalovirus promoter.

2) OBP-801 is a histone deacetylase (HDAC) inhibitor, having specific and strong activity on HDAC, which is expected to show anticancer effect by promoting an expression of tumor suppressor genes in cancer cell and inducing apoptotic and autophagic cell death.

3) OBP-601 (Censavudine) is a novel small molecule nucleotide reverse transcriptase inhibitor (NRTI) for HIV infection and is effective on a wide range of resistant virus strains.

**Peking University Gene 北大基因**

**Ms. 丽萍杨**

合伙人/VP

**Pfizer Inc 辉瑞**

**Mr. 元华 Yuanhua 丁 DING**

亚太外部科学创新总监 *Executive Director, Head of External Science & Innovation - APAC*

**Proswell 北京春天医药科技发展有限公司**

**Mr. 洋刘**

市场经理

**Mr. 艳雪李**

市场经理

**Ms. 妍谢**

市场经理

**Mr. 寅李**

首席商务官

**Mr. 青春宋**

总经理

**QIAGEN (Suzhou) Translational Medicine Co., Ltd 凯杰（苏州）转化医学研究**

QIAGEN (Suzhou) Translational Medicine Co., Ltd.

is an innovative company that provides complete solutions for precision medicine.

With a state-of-the-art facility equipped with the most advanced technologies and platforms as well as committed talents, QIAGEN (Suzhou) offers our partners with fully integrated solutions from biomarker discovery and lab testing development, patient stratification by molecular testing during clinical trials, to companion diagnostics (CDx) kit development and all the way to commercialization. Based on QIAGEN's advanced technology, and using our knowledge and experience in translational medicine, we hope to work with you to promote the clinical development rate innovative medicine to make personalized healthcare and improvement in life possible.

凯杰（苏州）转化医学研究有限公司是一个为精准医疗提供完整解决方案的创新型公司。凭借 QIAGEN 领先的仪器、试剂以及强大的技术团队，凯杰（苏州）能够为我们的合作伙伴提供从生物标志物的发现和检测方法开发、到新药临床试验病人分子检测和入组筛选，以及伴随诊断试剂盒开发和商业化的一站式服务。我们希望与您携手，通过凯杰先进的核酸和蛋白诊断技术，运用我们的转化医学知识和经验，加快新药临床开发的节奏，为中国待解决的医疗需求提供个体化诊疗解决方案。

**Website:**

[www.transmedchina.com](http://www.transmedchina.com)

**Mr. 亚飞 Nick 张 ZHANG**

总经理及首席执行官 *Chairman and CEO*

**Qiming Venture 启明创投**

**Ms. 敏 Irwin 王 WANG**

合伙人 *Partner*

**Mr. Shijie Ding**

## **Ractigen Therapeutics (中美瑞康医药科技(南通)有限公司)**

Ractigen Therapeutics is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

中美瑞康医药科技(南通)有限公司是一家初创型新药研发企业, 致力于研发以“RNA 激活”技术为核心的创新型药与疾病治疗方法。RNA 激活(RNAa)技术是目前唯一能够实现内源性基因激活并已进入临床验证的颠覆性技术, 它通过重新开启内源性基因的表达、恢复蛋白质的天然功能来治疗疾病, 有望填补现有靶向治疗药物只能抑制靶基因靶蛋白表达的巨大空白。中美瑞康由 RNA 激活领域的开拓者于 2016 年在中国江苏创立, 公司正在开发针对多个疾病领域的候选药物, 以解决高度未满足的临床需求。

### **Website:**

<http://www.ractigen.com>

### **Collaboration Opportunities**

licensing in/out; Financing/Investment/M&A/Collaboratio



### **Dr. Long-Cheng Li**

*董事长兼总经理*

*运营总监斐朱*

**Roche 罗氏**

**Mr. 在琪 Zaiqi 王 WANG**

*上海创新中心负责人 Head of Roche Innovation Center Shanghai*

**Sanwater Group 北京圣沃德生物科技有限公司**

*捷张*

*CEO*

**Servier 施维雅**

**Mr. Marcia Matos**

*Directeur R&D/ICTR Director at SERVIER Beijing Pharmaceuticals Research & Development Co, Ltd.*

**Shandong International Biotechnology Park 绿叶制药集团山东国际生物科技园**

**Mr. Tony 生姜 Jiang**

*产业园商业经理*

**Mr. 征李**

*产业园招商部负责人*



**Shang LIDE Biotech 上海立迪生物技术有限公司**

Shanghai LIDE has two subsidiary companies: Xian LIDE and Shanghai

LIWEN. LIDE is pre-clinical CRO, supporting oncology drug R&D

(Immun-Oncology, in vitro and in vivo). LIDE has 900 PDX, many are drug

resistant models. We have ready to go co-clinical trial cohort: PDX with matching

alive patients with full clinical information. Flow based immuno-oncology assays,

humanized mouse models, large molecule PK, ADA, immunogenicity analysis with

Simoa (digital PCR), etc. OncoVee Mini-PDX is LIDE patented technology that is 7

days in vivo drug sensitivity assay on mice. Clinical validation studies demonstrated

high correlation of Mini-PDX result vs clinical end point. ~10 PI Initiated Trials are ongoing for systemically validated the clinical correlation. The studies were registered at clinicaltrials.gov and clinical info was collected in RWE (Real World Evidence) format with standardized CRF that is FDA part 11 in compliance.

Shanghai LIWEN has medical license for independent 3rd party clinical testing lab, that is CAP certified in pathology and molecular pathology. LIWEN-Promega Joint Lab in China offer MSI, dMMR, TMB, PD-L1 testing to support Immuno-Oncology test at clinic.

As a translation medicine service platform, LIDE has extensive hospital collaboration (>100 hospitals) for companion diagnostic and biomarker studies.

**Website:**

[www.lidebiotech.com](http://www.lidebiotech.com)

**Collaboration Opportunities**

1. CRO service provider (in vitro, in vivo, Immuno-Oncology)
2. GLP central lab testing for translational biomarker studies at clinic. LIWEN is US CAP certified on Pathology and Molecular Pathology.
3. LIWEN-Promega Joint Lab at Shanghai offer MSI, dMMR, TMB, PD-L1 test in CAP certified GLP lab to support Immuno-Oncology Project
4. Large Molecule PK, ADA, Immunogenicity test with digital ELISA (Simoa) platform, that is 1000X more sensitive than regular ELISA
5. Clinical biomarker study. Ready to go cohort for Co-Clinical trial (PDX with matching alive patients)
6. 900 PDX models, 100 CDX, 80 Condition Reprogrammed primary cell lines, 50 PDX matching Patient Derived Cell lines.
7. Drug resistant model, e.g: Exon 19 del/T790M/C797S triple mutation PDX, PD-1, PD-L1 resistant PDX

**Professor Danyi Wen**

*President & CEO*

**Who I would like to meet in the conference?**

Pharma and Biotech that have CRO service needs

**Ms. 敏江**

*产品经理*

**Ms. 媛龙**

*助理总监*

**Shanghai Henlius Biotech, Inc. 上海复宏汉霖生物技术股份有限公司**

**Mr. 世高 Scott 刘 LIU**

*首席执行官 CEO*

**Shanghai HRAIN Biotechnology Co., Ltd 上海恒润达生生物科技有限公司**

**Ms. 礼丽 Lili 隋 SUI**

*总经理 General Manager*

**Shanghai LIDE**

上海立迪生物技术股份有限公司（以下简称“上海立迪”），致力于从事肿瘤转化医学及精准癌症医疗研究，协助药厂有效的进行新药开发和筛选，以帮助和指导医生进行临床用药，为患者提供个体化治疗方案的选择提供理论依据和指导。公司拥有 AAALAC 国际认证的 SPF 级实验动物中心、生物二级实验室、全自动免疫组织化学研究平台、细胞遗传学研究平台（形态学、核型、FISH 等）及世界一流的仪器设备。上海立迪已经与多家世界知名医药企业及国内 20 多家知名三甲医院在个体化治疗研究展开了多层次丰富的合作。上海立迪旗下有两家全资子公司“西安立迪生物技术有限公司”（以下简称“西安立迪”）和“上海立闻医学检验所”（以下简称“上海立闻”）。

西安立迪是上海立迪的全资子公司，公司座落于西安高新区瞪羚路 26 号现代企业中心。西安立迪与上海立迪共同致力于转化医学研究。我们使用最先进的技术，致力于鉴定和识别不同病人对抗肿瘤药物的反应。从事于将实验室研究成果转化为临床应用，

帮助和指导临床用药以及为病人提供个性化医疗服务。我们为药物的研发提供高质量的项目管理和咨询。由于保持高质量的服务，立迪正在被科学界，顶级药物研发公司以及生物技术公司所认可。

上海立闻是以分子诊断技术为主导的独立第三方医学诊断服务机构，上海立闻采用严格的质量体系和先进的管理系统，为客户提供卓越的临床检验及个性化用药研究等特色服务。

上海立闻医学检验所组建了以朱明华教授为代表的专业技术团队，同时聘请了美国梅奥诊所著名的学者专家为科学顾问，为临床提供专业的分子生物学、组织病理学和分子病理学检验，为肿瘤早期诊断、个性化治疗方案选择、疗效观察、预后判断、复发监测提供专业的检测和整体评估方案。

**Website:**

<http://www.lidebiotech.com/>

**Collaboration Opportunities**

PDX-centered in vitro and in vivo CRO capacities.

**Dr. Jijun Cheng**

*VP, R&D*

**Who I would like to meet in the conference?**

Pharma preclinical and clinical research.

**SUBIA 蓝石资本**

**Ms. 何季**

*VP*

**Suzhou Connect Biopharmaceuticals, Ltd. 苏州康乃德生物医药有限公司**

**Mr. 武宾 Wubin 潘 PAN**

*总裁 President*

**Suzhou Curegenetics 苏州克睿基因生物科技有限公司**

**Mr. 秋实李**

*COO*

**Suzhou Kintor Pharmaceuticals 苏州开拓药业有限公司**

**Mr. 友之童**

*总裁*

**Suzhou Rongsen Biotech 荣森（苏州）新药研发有限公司**

**Mr. 苏旺马**

*COO*

**SYNthesis Med Chem 苏州翔实医药发展有限公司**

SYNthesis (Suzhou) is preclinical small molecule drug discovery chemistry CRO. We focus on providing the world class medicinal chemistry and synthetic chemistry services by our western-trained medicinal chemists and China-based synthetic chemists. We work seamlessly with our client's research team to add capacity and insight to their drug discovery programs. SYNthesis provide cost effective and flexible chemistry service: from single compound custom synthesis, enriched library synthesis for hit-to-lead and lead optimisation under FTE arrangement; to risk-sharing integrated drug discovery projects.

Custom synthesis: with a very experienced synthetic chemists based in our Suzhou research facility, we have made a wide range of molecules such as classic heterocyclic molecules, nucleotides, chiral molecules including unnatural amino acids, ADC warheads and linkers, reference compounds and biological tools for chemical biology. We are well equipped to make molecule from mg till multi-kg scale. Medicinal chemistry: we believe that expert chemists provide the best chemistry and that expert biologists provide the best biology. As Chemistry CRO, we do however provide project management coordinating the interaction between the client, SYNthesis and an appropriate biology CRO to deliver an integrated drug discovery solution. The medicinal chemistry projects we have worked on can be first in class, fast follower, or a simple patent exemplification. We have also worked on a variety of

biological targets such as Kinases, Epigenetics, GPCR, HCV, and bacteria. SYNthesis focuses on H2L and LO phase of drug discovery. In last 4 years, 5 clinical candidates have been identified from the work we have carried out for our clients.

Risk-sharing drug discovery: Through our risk-sharing Platform, SYNthesis Research based in Australia, we have been working with world-class research organisations and pharmaceutical companies on this dual-contribution/dual-reward, shared risk collaborations, taking advantage of the Australian government's unique R&D tax incentive and SYNthesis med chem 's skills & capabilities in drug discovery chemistry.

**Website:**

[www.synmedchem.com](http://www.synmedchem.com)

### **Collaboration Opportunities**

financial investment, small molecule drug discovery collaboration, licensing out; M&A

**Mr. Xian Bu**

*执行董事总经理*

### **Who I would like to meet in the conference?**

financial investors to CROs and early stage small molecule drug discovery biotech; drug discovery companies seeking to outsource its medicinal chemistry; Chinese pharma seeking M&A opportunities

**TaiwanJ 景凯生技**

A clinical stage company NCE Discovery and Development for NASH, inflammatory diseases and oncology.

**Website:**

[Http://TaiwanJ.com](http://TaiwanJ.com)

### **Collaboration Opportunities**

Licensing out, Co-development and investment.

**Dr 英珠 Ying-Chu 石**

*董事長暨總經理*

### **Who I would like to meet in the conference?**

Pharmaceutical companies, Investors

**Tasly Holding Group 天士力控股集团有限公司**

**Mr. 鹤 Henry 孙 SUN**

*董事、副总裁 Vice President*

**TianFeng Capital 天峰资本**

A VC specialized in healthcare, located in Zhongguancun, Beijing.

**Dr. 巍孙**

*投资经理*

**Tigermed 杭州泰格医药科技股份有限公司**

**Mr. 锐 Peter 王 Wang**

*泰格医药商务发展与市场总监*

**Tigermed 杭州泰格医药科技股份有限公司**

**Ms. 东平张**

**Ms. 舒明张**

**Transcend Cytotherapy 海门雨霖细胞科技有限公司**

**Ms. 美茜 Meixi 陈 Chen**

**COO**

**TWi Biotechnology, Inc 安成生物科技**

TWi Biotechnology, Inc (TWi Biotechnology) is a clinical stage biopharmaceutical company based in Taipei, Taiwan.

The strategy of TWi Biotechnology is to focus on the development of treatments for unmet medical needs, such as severe rare diseases without therapies, or treatments that represent a significant breakthrough for the disease.

**Website:**

<http://www.twibiotech.com/>

### **Collaboration Opportunities**

AC-201 for Gout: Phase 2 with CFDA CTA

AC-203 for epidermolysis bullosa: Phase 2/3 with US FDA/ EMA IND

AC-701 for EGFR inhibitor induced skin rash: Phase 2

**Mr. Weishu Lu**

*Director of Product Development*

### **Who I would like to meet in the conference?**

1. out-license AC-201CR for China market development

2. in-license of small molecular new drug for US market

### **West Pharmaceutical Packaging(China) Company Ltd.**

**Ms. Iris 玮 Fu 付**

*Director*

**Ms. Catherine 静 Lee 李**

*Director*

**Wuxi apptec 药明康德**

**Mr. 群升 Qunsheng 冀 Ji**

*肿瘤及免疫事业部副总裁 VP, Head of Oncology and Immunology Unit*

**WuXi Biologics Cayman Inc. 药明生物技术有限公司**

**Mr. 竞 Jing 李 Li**

*副总裁, 生物制剂新药发现服务 Senior Vice President, Biologics Discovery*

**Zhejiang University 浙江大学**

**Mr. 卓贤孟**

*博导/国家青千*

**Zova Biotherapeutics 浙江昭华生物医药有限公司**

**Mr. 小冬曹**

*CEO*

**三生国健药业（上海）股份有限公司**

**Mr. 腾飞陈**

*BD Manager*

**上海优宁维生物科技股份有限公司**

**Mr. 兆武冷**

*总经理*

**Ms. 娃琪陈**

*副总经理*

**Ms. 丽丽吴**

*业务总监*

**上海立迪生物技术股份有限公司**

上海立迪生物技术股份有限公司，致力于从事肿瘤转化医学及精准癌症医疗研究，协助药厂有效的进行新药开发和筛选，并帮助和指导医生进行临床用药，为患者提供个体化治疗方案的选择提供理论依据和指导。目前平台已积累近 1000 例 PDX 模型及大量体内药效学数据，且连续两年多次通过 CFDA 的现场核查。同时涵盖 TCA、IHC、IF 等生物标记物检测等服务在内的立迪体外生物学服务平台以高质量的服务赢得了客户的高度认可

公司拥有 AAALAC 国际认证的 SPF 级实验动物中心、生物二级实验室、全自动免疫组织化学研究平台、细胞遗传学研究平台（形态学、核型、FISH 等）及世界一流的仪器设备。上海立迪已经与多家世界知名医药企业及国内 20 多家知名三甲医院在个体化治疗研究展开了多层次丰富的合作。上海立迪旗下有两家全资子公司—“西安立迪生物技术有限公司”（以下简称—西安立迪）和—“上海立闻医学检验所”（以下简称—上海立闻）。西安立迪是上海立迪的全资子公司，座落于西安高新区瞪羚路 26 号现代企业中心，与上海立迪共同致力于转化医学研究。

上海立闻是以分子诊断技术为主导的独立第三方医学诊断服务机构，采用严格的质量

体系和先进的管理系统，为客户提供卓越的临床检验及个体化用药研究等服务。目前立闻已经通过美国 CAP 官方认证，成为国内屈指可数的在病理和分子病理方面拥有 CAP 认证的临床医学检验所。这标志着公司病理检测质量管理和技术达到国际标准，实验数据可作为美国 FDA 药品认证的参考数据。

**Website:**

<http://www.lidebiotech.com>

**Collaboration Opportunities**

CRO Collaboration

**shuheng Li**

*BD Manager*

中信建投资本

**Ms. 淼桑**

*高级投资经理*

**Mr. 曦邹**

*VP 副总裁*

中国外商投资企业协会药品研制和开发行业委员会 **RDPAC**

**Ms. Angela 慧闫 YAN**

*高级总监科学与药政事务 Senior Director - Science & Regulatory*

中源协和细胞基因工程股份有限公司

**Mr. 思超王**

*战略品牌部*

**Mr. 博冯**

*学术经理*

**Mr. 鹏邓**

*战略品牌部*

北京科林利康医学研究有限公司

**Ms. 剑杨**

*BD Director*

**Mr. 宇夔王**

*BD Manager*

**Ms. 顺新蒋**

*BD Specialist*

**Ms. 灵燕廖**

*商务专员*

**Mr. 杰刘**

*商务专员*

国药资本管理有限公司

**Mr. 量邓**

*副总经理*

幂方资本

**Mr. 磊孙**

*投资副总监*

方恩(天津)医药发展有限公司 **Fountain Medical (TIANJIN) Co., Ltd.**

**Mr. 丹 Dan 张 ZHANG**

*董事长 Executive Chairman*

泰州医药城

**Mr. 伟李**

*招商中心副主任*

**Mr. 尧姚**

*招商三分局*



## 泰州医药高新技术产业园区招商中心

中国医药城，地处长江三角洲重要节点城市泰州，总体规划面积 30 平方公里，由科研开发区、生产制造会展交易康健医疗教育学综合配套由科研开发区、生产制造会展交易康健医疗教育学综合配套由科研开发区、生产制造会展交易康健医疗教育学综合配套由科研开发区、生产制造会展交易康健医疗教育学综合配套由科研开发区、生产制造会展交易康健医疗教育学综合配套由科研开发区、生产制造会展交易康健医疗教育学综合配套由科研开发区、生产制造会展交易康健医疗教育学综合配套等功能区组成，是中国等国家首级医药高新区首级医药高新区首级医药高新区首级医药高新区，由科技部、国家卫生计委，由科技部、国家卫生计委，由科技部、国家卫生计委，由科技部、国家卫生计委食品药监督管理局、国家中医与江苏省人民政府共同建设。

园区目前已经集聚国内外 60 多家知名大学和医药研发机构，雀巢、阿斯利康多家知名大学和医药研发机构，雀巢、阿斯利康武田制药、勃林格殷翰石集团海王业等近武田制药、勃林格殷翰石集团海王业等近 800 家国内外知名医药企业先后落户 1000 多项 “国际一流、国内领先” 的医药创新成果落地申报； 2800 多名海内外高层次人才落户创业， 45 人入选国家 “千人计划”；被列入国家新型疫苗及特异性诊断试剂产业集聚区发展点；启动开面积达到 18 平方公里。

中国医药城医药城医药城正在世界生物医药的浪潮中阔步前行，前行，前行，也在敞开胸怀拥抱各类医药创新资源，努力打造中国医药产业第一城

### Website:

<http://www.tzgxq.gov.cn/#>

**Mr. 彦照文**

招商六分局职员

**Ms. 林青万**

招商六分局局长

科锐国际

**Ms. Valisa 昕蔚 Li 李**

Senior Event Supervisor

**Mr. Yolanda Qin**

缔脉生物医药科技（上海）有限公司



**Mr. Zibao Zhang 张子豹**


BD Executive Director

**Who I would like to meet in the conference?**

Pharma/Biotech/Tech company CEO/CxO /R&D Head /Functional Head /BD Head/Procurement Lead et al

**Mr. 政 Jonathan 马 Ma**

Chief Data Scientist



**Ms. Yi Yan 严怡**

Executive Director, Head of Clinical Operations

**Who I would like to meet in the conference?**

The ClinOps persons of local pharma or other related persons.

**Mr. Portia Zhang 张向辉**  
*Associate Director, Quality Assurance*  
苏利制药科技江阴有限公司

**Mr. 法书马**

*执行总裁*

資元堂生物科技股份有限公司 (Zih Yuan Tang Biotech)

We are focusing on known small molecular drugs for new indications in diabetes and macular degeneration. GYT-002 is found that can effectively trigger secretion of insulin and insulin-dependence in therapy of diabetes, comparison with glibenclamid and metformin. Further, it has been in proof of applying in wound healing of diabetes. We have gotten the two US patents for GYT-002 on therapy and wound healing of diabetes in 2017. (patenting for CN, EU and JP) The other drugs GYT-088 is under working for macular degeneration. Recently, it showed the can effectively inhibit angiogenesis in study of macular degeneration.

專注於已知小分子藥物於針對糖尿病與黃斑部病變的新用途。開發出單一小分子藥物 GYT-002 同時促進胰島素分泌與提高對胰島素敏感度的作用，可用於糖尿病治療與其傷口癒合，於 2017 年獲得二項美國專利。(中國、歐盟與日本專利已在申請中) 另一小分子藥物 GYT-088，對於黃斑部病變治療的研究，發現其有效抑制血管新生。

**Website:**

<https://zih-yuan-tang.com>

**Collaboration Opportunities**

We are seeking for partners for clinical trail of GYT-002 and study of GYT-088 in financing. Either M&A or licensing out are also accepted.

More information, please wisiting <https://zih-yuan-tang.com/>

尋求投資者協助 GYT-002 的臨床試驗與 GYT-088 於黃斑部病變的研究，亦接受併購或專利授權。

更多的訊息，歡迎參訪 <https://zih-yuan-tang.com/>

**Dr. 隆誌 Lung JR 林 Lin**

*董事长顾问 (Consultant)*

**Mr. Chao Min Hsu**

*董事长*

**载愈医疗**

南京载愈医疗科技有限公司（以下简称“载愈”）位于江苏省南京市栖霞区江苏生命科技创新园 F6 栋 409 号，是一家拥有数十项专利技术，集医药技术、生物技术研发、技术转让为一体的高新型科技公司。

公司创始人鲍健博士及核心研发团队拥有超过 50 年以上的生物科技、医药开发、项目管理及制药行业经验。载愈依托核心研发团队在化学、药学及对肿瘤药物丰富的研究经验，自主研发了新型可生物降解合成聚合物，并将其作为传输载体，成功实现独有的“纳米靶向送药技术”。该技术不仅可以高效地传送各种已知抗肿瘤药物，并能大幅增强所搭载肿瘤药物的疗效，同时降低其毒副作用。

载愈将始终立足自主创新，不断研发具有工艺性先进、稳定性良好、溶解性全面、无病源污染等特点的独特纳米粒子制剂及新型送药系统，以全球化视野、开放性思维、创新型精神统领全局，坚持“多元化、品牌化、国际化”战略，深耕肿瘤医药领域，凝聚核心竞争力，将公司打造成肿瘤医药领域的佼佼者。

**Website:**

[www.zaiyumed.com](http://www.zaiyumed.com)

**Collaboration Opportunities**

投资

技术合作

临床服务

**Ms. Jian Bao**

*执行董事*

**Who I would like to meet in the conference?**

投资人  
临床实验服务商  
颐昂生物科技（上海）有限公司  
**Mr. 宇张**  
总裁兼首席执行官  
**Mr. 琪常**  
临床项目高级经理